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Purpose and objective:  In clinical practice, a constant value of 1.1 is used for the relative 
biological effectiveness (RBE) of protons, whereas in reality, the RBE is known to vary with 
the physical dose level, tissue type and biological endpoint. In order to investigate the 
heterogeneity of biological doses to structures associated with cognition in pediatric brain 
tumor patients, we included a wide selection of published models accounting for variable RBE. 
We also aimed to identify the most suitable RBE models for this endpoint and patient group 
through a criteria-based approach, and further use the identified models to estimate risk of 
cognitive impairment.  
 
Material and methods: Intensity modulated proton therapy (IMPT) treatment plans for ten 
anonymized pediatric patients with craniopharyngioma were re-calculated using using eleven 
published phenomenological models as well as two plan-based variable RBE models. Physical 
dose and linear energy transfer (LET) distributions were calculated on the planning Computed 
Tomography (CT) by using the FLUKA Monte Carlo code. Thirty brain structures associated 
with cognition (BSCs) were investigated in terms of RBE and dose/volume parameters 
associated with white matter damage (%V40Gy) and reduction of neural stem cell number 
(%V10Gy). The RBE models considered as most relevant for the studied endpoint were selected 
based on LET, tissue dependence and the number of data points used to fit the RBE models. 
The selected models were further used to estimate potential cognitive impairment, including 
change in intelligence quotient (IQ) and risk of memory impairment. To reflect the range of 
radiation fractionation sensitivity in the brain, (α/β)x values of both 2 Gy and 3 Gy were applied 
for the tissue dependent models.  
 
Results:  Across all RBE models, wide variations in RBE were seen for the studied brain 
structures. In terms of model selection, the models by Rørvik et al., McNamara et al. and Jones 
et al. fulfilled the defined selection criteria. The median [and range] of the dose-weighted mean 
RBE (RBEd) across all structures and models applied to one patient was 1.19 [0.81 – 2.61].  
Across the full patient cohort, the model by Jones et al. estimated the highest median RBEd of 
the selected set of models at 1.30 [1.15 – 3.31] across all structures, whereas the models by 
Rørvik et al. and McNamara et al. resulted in median values of 1.22 [1.12 – 2.46] and 1.23 [1.11 
– 2.62] including both input parameters of (α/β)x. In terms of change in IQ score, the median 
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across all IQ models was -1.9 [-9.3, 0.0] for the model by Jones et al., whereas the models by 
Rørvik et al. and McNamara et al. resulted in median values of 1.8 [-9.9, 0] and -1.8 [-10, 0.0], 
respectively. With a constant RBE of 1.1, the median IQ score change was -1.6 [-9.5, 0.0]. 
  
Conclusion: There was a large and systematic model-dependent variation in RBE and 
dose/volume parameters across the cognitive structures, also reflected in the estimated 
cognitive impairment. Through the criteria-based method, it was possible to select a set of 
endpoint-specific models that may give a more precise estimate of relevant RBE-weighted dose 
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In 2018, more than 34 000 new cancer cases were reported in Norway [1]. In the case of 
pediatric patients, central nervous system (CNS) brain tumors account for one-fifth of cancer 
occurrences and are the most common solid tumor in children [2]. Of these occurrences, 
approximately 6 – 9% are craniopharyngiomas [3]. Craniopharyngioma is a benign tumor 
located in the central part of the brain in close proximity to critical structures. 
Craniopharyngioma patients are therefore often vulnerable to toxicity, including cognitive 
impairment, despite a survival rate exceeding 85 % [4, 5]. An average loss of 18 intelligence 
quotient (IQ) points have been found in pediatric patients with brain tumors receiving radiation 
therapy, which illustrates the risk of cognitive impairment [6]. Due to the increased ongoing 
brain development compared to adults, pediatrics are of particular risk of developing 
neurocognitive impairment following radiation therapy.  
About 50 % of cancer patients will receive radiation therapy, either as a supplement to other 
treatment methods or as an independent treatment modality. Radiation therapy aims to deposit 
dose restricted to the tumor while sparing the surrounding healthy tissue. Protons in radiation 
therapy were first suggested by Robert Wilson in 1946 [7]. The rationale behind this suggestion 
was that protons deposit most of their energy at the end of their range, resulting in a sharp peak, 
known as the Bragg Peak. Compared to photons, protons result in better dose conformity with 
lower integral dose and no “exit” dose [8, 9]. Proton beam therapy may, therefore, better spare 
healthy tissues, including brain substructures associated with cognition (BSCs), potentially 
preserving cognitive function and IQ points [10]. Radiation therapy using photons is to date 
much more common than proton beam therapy; however, proton beam therapy is increasingly 
being used for treatment of craniopharyngiomas, and the clinical results are promising when 
compared with photons [11-14]. However, there are uncertainties regarding radiation therapy 
with protons. For instance, the relative biological effectiveness (RBE) of protons compared to 
photons is still, to a certain degree, unknown. In clinical practice, a constant RBE value of 1.1 
is being used, although the RBE has been shown to vary with both biological and physical 
factors [15]. The enhanced linear energy transfer (LET) at the distal end of the beams is of 





The overall objective of this thesis was to evaluate how the RBE-weighted dose to brain 
structures associated with cognition differs when using a constant RBE of 1.1 and so-called 
variable RBE models. A recent study by Toussaint et al. demonstrated that cognitive functions 
might be better preserved with protons compared with photons for children with 
craniopharyngioma [13]. There have been several studies reporting less cognitive impairment 
following proton therapy treatment than photon therapy; however, most of these studies neglect 
the potential increased biological effectiveness of protons [11, 12]. The constant value of 1.1 
used for the RBE of protons may lead to an under- or overestimation of the deposited dose, and 
therefore may influence the risk of side-effects.  
Phenomenological and so-called plan-based variable proton RBE models have endeavored to 
account for the physical and biological variations in RBE estimation. None of the published 
models are to this day in clinical use; however, they might contribute to relevant material in 
clinical outcome interpretation [17, 18]. Recently, Rørvik et al. showed that both the input data 
and estimations varied considerably between the models, highlighting the complexity in 
interpretations of the RBE.  
For this thesis, it was of interest to investigate a large number of BSCs. Most studies in the field 
of cognitive impairment in pediatric brain tumor patients have tended to focus on large brain 
structures and brain regions, such as the supratentorial brain or temporal lobes [10, 19-22]. 
However, recent research has suggested that smaller substructures may have a substantial 
impact on cognitive function outcomes following radiation therapy [23-25].  
The overall goal of this thesis can be split into two separate aims, which are closely related. 
First, we aimed to identify a set of variable proton RBE models well suited for the patient group 
(pediatric craniopharyngiomas), combined with the specific endpoint (cognitive impairment). 
Secondly, we aimed to estimate the possible range of RBE-weighted doses, RBE, and 
dose/volume parameters to the BSCs, which eventually could be used to estimate cognitive 
impairment for the patient group. Results from this thesis will hopefully provide information to 
advance the understanding of variable RBE doses related to cognitive impairment for pediatric 
brain tumor patients receiving proton therapy.  
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2 Radiation therapy 
Radiation therapy has been used in cancer treatment for more than a century. The life 
expectancy for cancer patients has been significantly improved over the last decades [26]. 
Enhanced imaging techniques and improvement of radiation treatment have been a critical 
source in the improvement of survival rates. Today, about 45-50% of all cancer patients will 
receive radiation therapy either as a supplement to surgery and chemotherapy or as an individual 
treatment modality [27]. The aim of all types of radiation therapy is to deposit sufficient dose 
to control the tumor while sparing healthy tissue.  
Treatment with highly energetic photons is to date the most frequently used form of radiation 
therapy. Radiation therapy with protons as an alternative to photons are increasingly being used 
worldwide. The rationale for radiation treatment with protons compared to photons is the 
favorable depth-dose distribution, which reduces radiation dose to normal tissue. As of 2018, 
more than 180 000 patients were treated with proton therapy, of which approximately 10% of 
these were children [9, 28]. 
2.1 Physics of photon therapy 
This project mainly focuses on proton therapy; however, due to the large extent of photons in 
radiation therapy some of the basic physics of photon radiation therapy will be presented briefly 
in the current sub-chapter. A photon is a neutrally charged and massless particle. Photons (also 
x- and ɣ-rays depending on energy) interacts with matter primarily by three processes, which 
contribute to energy absorption; photoelectric effect, Compton scattering and pair production 
[29]. These interactions are dependent on the photon energy (typically 4 – 25 MeV), the density 
and the atomic number, Z, of the absorbing material.  
When photons interacts with a medium, they transfer their energy to electrons, which in turn 
will impart energy to surrounding tissue by producing ionization and excitation of atoms [29]. 
Photons are therefore considered indirectly ionizing. The intensity of the initial photon beam 
will be continuously reduced with depth when traversing matter, and the change in intensity 
can be found by the following exponential equation: 
                     I(x) = I0e
−μx ,      (2.1) 
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where I(x) is the intensity transmitted by a thickness x, Io is the initial photon beam intensity 
and μ is the linear attenuation coefficient of the given material. The linear attenuation 
coefficient is closely related to the sum of contribution from each interaction process [30], 





,       (2.2) 
where NA is Avogadro's constant, A is the atomic mass and μ/ρ is the mass attenuation 
coefficient.  
As seen in Figure 2.1, the photon dose deposition increases with depths in tissue towards a 
maximum. This region is commonly referred to as the build-up region and is due to the range 
of high-speed electrons produces by the photon beam at the surface of the patients [29]. This 
maximum is positioned within a few cm inside the tissue, dependent on the initial beam energy 
and treatment field size. Beyond the point of maximum, the dose deposition decreases 
exponentially due to photon attenuation. 
2.2 Physics of proton therapy 
This chapter aims to describe the essentials of proton therapy physics. Firstly, the capability to 
deposit energy through ionization of the tissue is shared by all types of radiation. However, the 
interactions which lead to deposition of energy in tissue differ between charged particles and 
neutrally charged particles, as e.g. photons. Charged particles have the potential to directly 
ionize material, whereas photons have to experience an indirect interaction with particles 
capable of direct ionization [29].  
Protons, as seen in Figure 2.1, deposit most of the dose near the end of the range of the proton 
beam, followed by a sharp dose fall-off. As the range of the protons is highly dependent on the 
primary beam energy, the position of the maximum dose deposition can be placed within the 
target volume. Compared to photon therapy, these physical characteristics can lead to a lower 
integral dose and no exit dose while still delivering a uniform dose to the target volume. Proton 
therapy, therefore, can spare normal tissue, which is an important aim when treating tumors 




2.2.1 Stopping power 
The stopping power for a charged particle is the average loss of energy dE per unit length dx in 
a medium, generally given in units of keV/μm. This rate of energy loss is mathematically 















) − 2β2 − δ − 2
C
Z
]     (2.3) 
Table 2.1: Description of parameters used in the Bethe-Bloch equation. 
Variable Definition Unit and value to the variables 
𝐍𝐚 Avogrado’s constant 6.022 x 10
23 mol−1 




𝐜 Speed of light in vacuum 2.998 x 108 ms−1 
𝐙 Atomic number of absorbing material  
𝐀 Atomic weight of absorbing material g mol−1 
𝐳 Charge of incident particle  
𝛃 Relative particle velocity to the speed of light  
𝐯 Projectile velocity ms−1 
𝐫𝐞 Electron radius 2.818 x 10
−15 m 
𝐈 Mean excitation potential eV 
𝛒 Density of the absorbing material g cm−3 
𝐖𝐦𝐚𝐱 Maximum energy transfer from a single 
collision 
 
𝛄 Lorentz factor  
𝛅 Density correction  
∁ Shell correction  
 
Table 2.1 presents a description of the parameters in the Bethe-Bloch equation. As seen by 
equation (2.3), the deposited energy is inversely proportional to the square of the velocity of 
the particle. In other words, protons deposit more dose at low velocity and less dose at high 
velocity [32]. This leads to a maximum dose deposition at the end of the path, commonly 
referred to as Bragg Peak [33] (Fig 2.1). The characteristic of the Bragg peak is shared by all 
heavy charged particles. However, the sharpness and relative height of the peak increases with 
increasing mass [32].    
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The initial beam energy for a proton beam is typically from 70 – 230 MeV [29]. The range of 
the particles is defined as the depth at which half of the particles in the material have come to 
rest [34]. The penetration depth of the charged particles is determined by the initial energy, 
material composition and density of the material. However, as the particles will endure different 
interactions as they travel through the material, the range of each particle differs. This 
determines the width of the Bragg peak and is known as range straggling. To accomplish the 
same depth in material as lighter ions, e.g., protons, heavier ions need higher energy, which can 
be seen from the particle charge, z, in the Bethe-Bloch equation (Eq. 2.3). The monoenergetic 
proton beam reaching the head of the treatment delivery system creates a narrow peak, called 
the pristine peak. In order to cover the entire target volume, multiple pristine peaks of different 
energies and ranges are added together to create a flat dose plateau, which is known as a spread-
out Bragg Peak (SOBP) [29].  
 
 
Figure 2.1: Comparison of the longitudinal depth dose distribution of protons (solid blue line) and 
photons (solid red line). The SOBP is shown by the dashed blue line [35]. Photons have a maximum 
dose deposition within a few centimeters before the dose exponentially decreases. Protons deposits a 




2.3 Interactions of charged particles in matter 
The deposition of energy from protons is highly energy dependent. At therapeutic proton beam 
energies, protons interact with human tissue mainly through three interactions; coulomb 
interaction with atomic electrons or the atomic nucleus, or nuclear interaction [27]. 
2.3.1 Coulomb interactions with atomic electron  
Particles with mass greater than the rest mass of an electron are considered heavy charged 
particles [29]. Coulomb interaction with an orbiting atomic electron is the leading cause of 
energy loss of heavy particles traversing through a medium. In these interactions, protons lose 
some of their kinetic energy by ionization and excitation of atoms. When a bounded electron is 
raised to higher energy levels, the process is called excitation. The process is determined as 
ionization if the radiation has adequate energy to eject an electron from the atom [36]. This 
causes an electron to be ejected from the atomic orbit. The electron will further deposit the dose 
locally due to the short range of the electron.  
2.3.2 Multiple Coulomb scattering 
When a proton passes a nucleus with a distance smaller than the atomic radius, the repulsive 
force of the nuclei changes the trajectory of the protons [26]. The repulsive force causing the 
deflection away from the original trajectory is due to the positive charge for both the proton and 
nuclei. The scattering angle is dependent on the material. These interactions do not result in the 
loss of energy of the protons. However, the sum of multiple scattering processes leads to the 
deflection of the original path, causing a lateral broadening of the original beam.  
2.3.3 Inelastic nuclear interactions 
Nuclear interactions, often referred to as non-elastic collisions, occurs when a proton is 
absorbed by an atomic nucleus. Compared to interaction processes causing ionization and 
excitation, non-elastic collisions are less likely to occur. In these interactions, the incoming 
protons knock secondary particles, i.e., protons, neutrons or ion clusters, out of the atomic 
nuclei [37]. In most cases, the secondary particles have relatively low energy compared to the 
incoming proton. Despite the low probability of occurrence compared to interactions with 
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electrons and Coulomb scattering, non-elastic collisions are accounted for when planning 
proton radiation therapy [37].  
2.4 Dosimetry 
2.4.1 Absorbed dose 
The absorbed dose, which is the most common quantity used in dosimetry, is defined as the 
radiation energy imparted per unit mass of an irradiated body [29]. The quantity absorbed dose, 
D, is a function of the mean energy, ∆E, imparted to the material of mass ∆m by ionizing 




 ,       (2.4) 




3 Treatment planning and delivery 
Treatment planning refers to a multi-step process that typically starts with image acquisition 
and defining volumes of interest. Further, the radiation dose deposition needs to be prepared 
using dedicated software. This process also includes selection of treatment delivery technique 
and choice of beam angles and energies [29]. The intention of treatment planning is to deposit 
dose restricted to the tumor while sparing healthy tissue. To achieve successful treatment, 
thorough planning prior to radiation therapy treatment and accurate execution is a necessity. 
The following chapter will introduce some important concepts of radiation therapy planning 
and delivery.  
3.1 Volume definitions 
The International Commission of Radiation Units (ICRU) Report 50 labeled various dose and 
volume specifications in radiation therapy. These specifications are presented in Figure 3.1. In 
ICRU report 50, the gross tumor volume (GTV) was defined as the gross demonstrable extent 
and location of the tumor [38]. This tumor volume usually consists of the primary tumor and 
metastasis (spread of cancer cells) [29, 39]. The clinical tumor volume (CTV) is an extension 
of the GTV and represents the assumed tumor volume. To successfully achieve the therapeutic 
aim, the prescribed dose should cover the CTV [29].  In order to account for deviations in the 
CTV due to anatomical motion, an internal margin (IM) is added to the CTV [38]. The volume 
which contains the CTV and the IM is the internal target volume (ITV).   
The PTV is, as stated by the ICRU Report 50, a statistical concept which accounts for all 
possible geometrical deviations and inaccuracies [39]. This volume contains the CTV and 
accounts for all uncertainties, e.g. patient motion and setup error, by adding a margin of error 
to make sure that the prescribed dose is delivered to the CTV. Most of the defined volumes 
holds for both photon and proton therapy. A later report dedicated to proton therapy from the 
ICRU, Report 78, suggested that the traditional concept of PTV was not feasible in proton 
therapy [40]. Due to the range uncertainties of a particle beam, an additional margin should be 




Figure 3.1: Schematic illustration of volumes and margins related to radiation therapy as defined by the 
ICRU [38]. The internal margin, IM, compensates for anatomical variations in the CTV. The GTV and 
CTV is modality independent, whereas the margin between the CTV and PTV differs between photon- 
and proton therapy.  
3.2 Plan evaluation 
An important tool in evaluating treatment plans is the Dose Volume Histograms (DVH). The 
DVH displays the dose as a function of volume in either percent or absolute value within a 
volume of interest. Therefore, the DVHs are an essential tool to reduce the dose in healthy tissue 
as much as possible.  
When assessing the effect of radiation on the tumor volume and the normal tissues, the tumor 
control probability (TCP) and normal tissue complication probability (NTCP) are commonly 
evaluated. These sigmoid-shaped dose-response curves (Fig. 3.2) are grounded on the 
assumption that increased dose will increase the tumor response and damage to normal tissue 
[41]. The distance between the two dose-response curves, known as the therapeutic ratio or 
therapeutic window, describes the likely difference between TCP and NTCP and is thereby a 
measure of the quality of a radiation treatment plan. An important aspect of radiation treatment 





Figure 3.2: Illustration of the sigmoid-shaped dose-response curve for TCP (blue) and NTCP (yellow) 
[42]. The distance between the two curves, the therapeutic ratio, should preferably be as wide as 
possible. 
3.3 Medical imaging in radiation therapy 
In order to deliver the dose accurately to the patient, precise reconstruction of the patient 
anatomy is a necessity. Typically, a 3D anatomical model is created by the use of Computed 
Tomography (CT). Also, magnetic resonance imaging (MRI) and positron emission 
tomography (PET) are used to complement additional anatomical data to construct a precise 
anatomical model of the patient. Pediatric CNS tumors MRI offer more soft tissue contrast, 
allowing for more accurate normal tissues and tumor volume definition, whereas PET offers 
functional information, mostly used for target volume definition. The CT data provides a 3D 
electron density map of the patient, which is used in the delineation of the target volume and 
critical structures, in addition to the calculation of the dose distribution within the patient [43].  
3.4 Dose calculation algorithms 
CT images of the patients anatomy, including delineated structures and volumes, are imported 
to treatment planning software, known as treatment planning systems (TPS). TPS gives an 
estimate of how the dose is delivered to the patient by using pencil-beam algorithms. The 
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pencil-beam algorithms are based on mathematical models that simulate individual protons 
through a volume represented by a rectangular 3D grid of voxels [37]. The pencil-beam 
algorithms are considered to be highly accurate; however, in low-dose regions, the algorithm is 
less sensitive to density variations when compared to the Monte Carlo (MC) method [37], which 
is currently more widespread within research. 
The Monte Carlo (MC) technique is acknowledged as the superior method of simulating particle 
interactions and dose depositions. In a study that compared pencil-beam algorithms and the MC 
method, Ma et al. found a difference in dose distribution near tissue inhomogeneities of 5 % 
[44]. MC simulations are widely being used to validate and support TPS, and are expected to 
be more implemented in treatment planning in the years to come [29, 45, 46].  Overall, TPS 
generally rely on the pencil-beam algorithms as this method has favorable computation time 
and provides reasonable accuracy.  
3.5 Treatment delivery 
3.5.1 Particle accelerators 
Two types of accelerators are used to generate protons with adequate energy for therapeutic 
purposes; synchrotrons and cyclotrons. Cyclotrons operate at fixed-energies up to 250 MeV, 
which has a range of approximately 38 cm in water [24]. A strong magnetic field bends the 
constant particle beam trajectory into a spiral path. In the spiral path, the particles gradually 
gets accelerated, which increases the radius throughout the spiral-shaped motion. When the 
particles are accelerated to maximum energies, the particles can be steered to a beam transport 
system [47]. A material with adjustable thickness, commonly known as an energy degrader, is 
used to develop an SOBP by varying the beam energy.   
In synchrotrons, the particle beam is steered in a circular motion by magnets inside a ring-
shaped vacuum tube [29]. As opposite to cyclotrons, synchrotrons can adjust the particle beam 
energy to desired levels without using energy degraders.   
3.5.2 Beam delivery techniques 
The accelerated protons are delivered to the patient by one of two methods; passive scattering 
or active scanning. The two delivery techniques are shown in Figure 3.3. In the case of active 
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beam shaping, often referred to as Pencil Beam Scanning (PBS), the treatment delivery system 
guides a narrow beam to three-dimensional grids (voxels) using dipole magnets [29]. The 
particle beam is steered magnetically both horizontally and vertically, while the beam energy 
determines the depth of the Bragg peaks. Intensity modulated proton therapy (IMPT) is 
increasingly being used as a scanning technique. In IMPT, the dose distribution is constructed 
by multiple fields with non-uniform dose distribution, which when combined delivers a 
homogenous dose to the target volume. Compared to passive scattering, active scanning results 
in a favorable integral dose. This delivery technique is, however, sensitive to organ motion [29].  
In passive scattering, the primary proton beam is scattered by placing materials of low-atomic 
number in front of the monoenergetic beam [29]. Dependent on the field size, the beam is 
scattered by one or two (double-scattering) materials. In order to deliver the dose restricted to 
the target volume, the scattered beam is shaped by collimators. In passive scattering, rotating 
filters are used as range modulators to achieve the desired SOBP within the target volume. The 
rotating filters vary in thickness, which allows the beam to be attenuated to a preferable energy. 
Due to interactions between the particle beam and nuclei in the collimators, nuclear fragments 
from these interactions will cause an elevated dose deposition which might harm normal tissue.  
 
Figure 3.3: Illustration of proton delivery techniques [9]. In passive scattering (upper), the beam is 
scattered by a low Z material placed in front of the initial beam. Collimators and compensating filters 
are further used to adjust the beams shape and energy distribution. The active scanning technique (lower) 




4 The biological effect of ionizing 
radiation 
Radiobiology involves the study of ionizing radiation interaction with living cells or tissues, 
and includes both physical and biological aspects. The physical aspect involves interactions 
between charged particles and atoms or molecules within the tissue [41]. These interactions 
cause damages, or lesions, within the cells and produce biological damage. 
The physics of charged particles is well understood. However, the biological impact of charged 
particles is not yet fully exploited [48]. To completely take advantage of the superior physical 
characteristics of particles compared to photons in radiation therapy, a better understanding of 
particle radiobiology is needed.  The following chapter will summarize the main reasons for the 
differences in biological impact for protons compared to photons.  
Radiation-induced damage is caused by either direct- or indirect action, as illustrated in Figure 
4.1. In high LET-radiation, direct actions are dominant. In direct action, the secondary electron 
affects the DNA directly. In terms of indirect action, the biological damage is done when the 
radiation is absorbed in the material and releases charged particles [36]. The radiation interacts 
with atoms or molecules and produces free radicals (unstable atoms), which in turn will produce 
biological damage. The indirect action mainly occurs by ionization of water molecules due to 
the high concentration of water (approximately 80 %) in cells. The ionized water molecules 
produce highly reactive radicals called hydroxyls (OH), which causes biological damage. In 
terms of photon radiation, approximately two-thirds of the damage to the DNA is caused by 
OH [49].  
DNA is the main target for radiation-induced cell killing [41]. The DNA consists of two strands 
in a helix-shaped structure which hold genetic information. Ionizing radiation produces lesions 
within the DNA, either through a single-strand break (SSB) or a double-strand break (DSB). In 
general, indirect action causes more SSB in comparison to direct action. Due to DNA repair 





Figure 4.1: Illustration of direct and indirect action. In indirect action (top of the figure), the secondary 
electron interacts with a water molecule and produces a hydroxyl radical which will damage the DNA. 
In direct action (bottom of the figure), the secondary electron damages the DNA directly. The illustration 
is transferable to proton interactions [49]. 
4.1 Linear quadratic model 
A plot of the surviving cell fraction against radiation dose, as illustrated in Figure 4.2, is known 
as a cell survival curve [41]. The biological response of cells to radiation is mathematically 
described by the linear-quadratic (LQ) model. In this model, the surviving fraction is given as  
     S(d) = e−αd−βd
2
,       (4.1) 
where d is the dose, and α and β are tissue parameters. The linear component of the equation, 
exp(-αd), is suggested to describe lethal single-track events as double-strand breaks in the DNA. 
The quadratic component, exp(-βd2), represents the probability of two-track events causing 
lethal damage [41]. In a cell survival curve, the two tissue-specific parameters α and β 
represents the initial and final slope, respectively.  
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The two tissue-specific parameters, α and β, have dimensions Gy-1 and Gy-2, respectively. The 
ratio of these two parameters, α/β, is often used to quantify the radiation fractionation of tissues 
[41]. For early responding tissue, e.g., tumors and skin, the range of α/β ratio values are between 
7 - 20 Gy [41]. In the case of late responding tissue, such as brain structures and the spinal cord, 
values of the α/β ratio are typically between 0.5 to 6 Gy [41]. The reference radiation 
fractionation sensitivity is commonly given as (α/β)x for photons.  
 
Figure 4.2: Illustration of dose-response curves for mammalian cells high LET-radiation and photons. 
Modified from Hall (2012) [49].  
Cell survival is usually quantified as a function of dose from either in vivo or in vitro 
experiments. In vitro experiments are defined as experiments conducted outside of a living 
organism, whereas in vivo experiments are performed inside living organisms [41]. The most 
frequently used cell lines for in vitro experiments are Chinese hamster lung fibroblast cells 
(V79), in addition to HeLa cells (human cancer cells) and CHO cells (Chinese hamster ovary 
cells) [30]. The most commonly used cell lines, V79 cells, are characterized by a low (α/β)x 
ratio and have a lower number of chromosomes when compared with human cell lines [50]. 
Clonogenic cells, or colony-forming cells, are defined as cells that are able to proliferate 
indefinitely and form colonies within a defined growth environment [41, 49]. Clonogenic cell 
survival is the most studied endpoint.  
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4.2 Linear energy transfer 
The term Linear Energy Transfer (LET) was first introduced by Zirkle et al. in 1952 [51]. This 
term describes the ionization density along a particle trajectory and is commonly given in units 




,       (4.2) 
where dE∆ is the mean energy lost by charged particles due to electronic interactions, dl is the 
traversed distance and the ∆ is the energy cut-off. If no energy cut-off is considered, i.e. ∆ = ∞, 
the LET is equal to the stopping power and is referred to as unrestricted LET (LET∞) [53]. 
Proton beams are typically referred to as “low-LET”-radiation compared to heavier ions for 
clinically relevant energies, and LET values from 1 – 10 KeV/μm are common in therapeutic 
beams [27].  
Both restricted and unrestricted LET applies to mononergetic beams only, whereas in reality, 
proton beams consist of particles with a wide range of different LET values. For simplicity 
when studying the biological outcome, the unrestricted dose-averaged LET (LETd) value is 









       (4.3) 
In this equation, the term Sel(E) is the electronic stopping power of a proton with kinetic energy 
E, and D(E,z) is the absorbed dose by a proton with kinetic energy E in the tissue at location z 
[54].  
The LET is a measure of the quality and efficiency of a beam. An increase in LET will, in 
general, produce more cell killing per Gray [41]. This can be seen by the steepness of the 
survival curve, which was presented in the previous chapter (4.1). Also, the survival curve 
becomes straighter with a less distinct shoulder with high LET-radiation. The latter is suggested 
to be explained by less probability for the cell to repair from high LET-radiation as compared 




4.3 Relative biological effectiveness 
The deposited dose from different types of radiation does not result in equal biological effect. 
The relative biological effectiveness (RBE) serves as a link between the vast knowledge on the 
biological effect of photon radiation and transfers to proton radiation. In general, a lower 
absorbed dose with proton therapy is needed to achieve the same biological effect compared 
with photons. In the context of proton therapy, the RBE is defined as the ratio between photon 
reference dose, Dx, and proton dose, D, achieving the same biological effect. The relationship 
for the RBE is shown below: 
 
   RBE =
Dx
D
           (4.4) 
 
The RBE-weighted dose is commonly used to quantify treatment expectations [55]. The RBE-
weighted dose is given as the RBE multiplied with the dose, and is measured in Gy(RBE). In 
clinical practice, patients treated with protons are typically prescribed with doses where the 
photon-equivalent RBE-weighted dose matches the photon physical dose [56]. In this manner, 
the RBE-weighted dose to the patient is equivalent to the physical photon dose divided by the 
RBE.  
 
A generic value of 1.1 is recommended for RBE in clinical use by ICRU [57]. This value was 
adopted based on in vitro and in vivo experiments [58]. On average, RBE can be considered 
between 1.1 and 1.15 from the entrance to the center of an SOBP, then increases to ~ 1.35 at 
the distal edge, and increases to ~1.65 in the distal fall-off [59]. The value of 1.1 was suggested 
as an average over various endpoints, fractionation over 2 Gy, and at the center of the target 
volume [59]. An assumption of an average over various endpoints may not be sufficient as 
recent studies have shown RBE to vary depending on the endpoint.  An RBE at the center of an 
SOBP was found to be 1.22 ± 0.02 of in vitro experiments, while in vivo experiments provided 
a value of 1.10 ± 0.01 [59]. 
4.3.1 Dependencies of relative biological effectiveness  
The RBE is dependent on several factors, including the quality of radiation, dose, and the 
biological endpoint. The different RBE dependencies will be explained in the following sub-
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chapter. Firstly, the LET has a central role in estimates of the RBE. Most experiments show an 
approximately linear increase in RBE with increasing LET [59].  
High LET radiation has increased biological effectiveness compared to photons, due to higher 
production of non-reparable lesions with increased ionization density [60]. As shown in section 
4.2, the LET is dependent on beam energy and will increase as the protons slow down. The 
RBE has been shown to increase along the track of the protons and result in the highest value 
in the distal end. This is also where the LET value is at its highest. In the center of an SOBP, 
the LET value is potentially ~ 5 keV µm-1, and in the sharp fall-off at the distal end of the peak, 
the LET value may be ~ 20 keV µm-1 [59].  
The biological effectiveness reaches its maximum at LET values of approximately 100 keV/μm 
and decreases beyond this point [41]. Radiation with LET above 100 keV/μm deposits more 
energy than what is required to kill the cell [41]. This overkill effect is illustrated in Figure 4.3. 
In the clinical use of protons, LET values over 30 keV µm-1 are not common, even though LET-
hotspots may occur. 
 
Figure 4.3: Illustration of the RBE dependence on LET, also explaining the phenomenon of cell overkill 
from high LET radiation [61]. The survival fraction (SF) levels are shown right in the figure.  
In addition to the LET dependency, the RBE is also tissue-dependent. Experimental data have 
shown a clear trend of increased RBE with decreasing (α/β)x [58]. The current value of 1.1 is 
suggested to underestimate RBE at low (α/β)x and overestimate the RBE at high (α/β)x [59], 
and especially organs at risk with low (α/β)x within proximity of high LETd values may be 
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underestimated in terms of RBE [62]. In terms of dose dependency, experimental in vitro and 
in vivo data show higher RBE as the dose decreases [58].  
4.3.2 Published models accounting for the variable relative biological 
effectiveness 
Several phenomenological models have been developed to include variations in the physical 
and biological parameters in the estimation of variable RBE [63-75]. Recently, Rørvik et al. 
compared eleven phenomenological models as well as two plan-based variable RBE models 
[76]. The two plan-based variable RBE models, Frese et al. (FRE) and Unkelbach et al. (UNK), 
are mainly models for LET optimization and are not fitted to in vitro data but based on 
information from treatment plans [63, 72]. These models assume an RBE linearly dependent 
on LETd and that the average RBE inside the target volume is 1.1.  
 
The phenomenological models explored by Rørvik et al. are derived from fits to existing 
experimental in vitro data and grounded on the LQ model. This is also the case for the suggested 
variable proton RBE model by Chaudary et al. [64]. In the context of the LQ model, a general 
expression for the RBE can be written as a function of physical dose deposited per fraction, DP, 
and the biological tissue-parameters α and β, and αx and βx for protons and photons, 
respectively. The general expression is shown in equation (4.6).  






















               (4.5) 
 
The RBE at the lower and upper limit of the physical dose, i.e. lower and upper limit of 
surviving fraction, is commonly given as RBEmin and RBEmax, respectively [77, 78]. The two 




RBE = RBEmax =
α
αx
       (4.6) 
lim
D→∞
RBE = RBEmin = √β/βx        (4.7) 
 


































)       (4.8) 
 
Equation (4.8) is shared by all variable RBE models based on the LQ model [76]. The 
dissimilarities between models based on the LQ model in terms of the equations are the 
definition of the RBEmax and RBEmin. In addition to the difference in the formalism of the 
RBEmin and RBEmax, the variable RBE models are based on different experimental data and 
utilized different regression techniques in model fitting. Experimental RBE values have been 
shown to vary both across and within different cell lines [59].  
 
Most models are based on experimental in vitro databases. The models by Chen and Ahmad 
(CHE), Wilkens and Oelfke (WIL), and Carabe et al. (CAR) are all exclusively based on the 
V79 cell line. As these models only are derived from one cell line, the range of (α/β)x values is 
constricted, which can be observed in the right panel in Figure 4.4. These models may be 
inapplicable to some patient cases where the radiation fractionation sensitivity is higher or 
lower than in the studied cell line. Experimental data from various in vitro studies based on the 
survival of V79 cells indicate a higher RBE compared with other cell lines [27]. The V79 cell 
may, however, be more relevant for low (α/β)x values in brain tissue. 
 
By the use of multiple cell lines, a greater range of (α/β)x values is achieved by some of the 
models. The models by Peeler (PLR), Tilly et al. (TIL), Wedenberg et al. (WED), Jones (JON), 
Mairani et al. (MAI), McNamara et al. (MCN), Chaudary et al. (CHD) and Rørvik et al. (ROR) 
use multiple cell lines and therefore have a broader range in terms of (α/β)x values.  
CHD and PLR use human cell lines. The analyzed cells in the PLR model are H460 and H1437, 
whereas the cell lines used in the CHD model are AG01522 and U87. The CHD model and all 
variable RBE models explored by Rørvik et al. besides WIL, CHE and UNK are tissue 
dependent, i.e. dependent on (α/β)x. The JON and FRE models utilizes αx and βx separately 
instead of the ratio between the two tissue-specific parameters. 
Of the eleven phenomenological models explored by Rørvik et al., all models with the exception 
of CHE, ROR and PLR assume a linear relationship of RBE as a function of LETd. This 
assumption also applies to the CHD model. Rørvik et al. developed two variable RBE models, 
using different statistical weighting for the two suggested models [66].  
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As seen in the left panel of Figure 4.4, there is a considerable variation in LETd values of data 
points in databases across all models. CHE, TIL, MAI and WED have no LETd data points 
below 7.7 keV µm-1. For these models, the lack of datapoints is accounted for by extrapolation 
from high LETd data 
 
Figure 4.4: Distribution of LETd (left) and (α/β)x  (right) values from the databases of each model. The 
plot has been modified from Rørvik et al. [66] by adding values for Chaudhary et al. [64] and removing 
values for the model by Belli et al. [79]. As seen in the right panel, a broader range of (α/β)x values is 




5 Cognitive impairment of pediatric CNS 
tumor patients after radiation therapy 
Despite being a vital treatment technique when curing cancer, radiation therapy treatment might 
damage healthy tissue and affect cognitive domains. Preservation of healthy tissue is one of the 
primary concerns when treating with radiation therapy. Quality of life is considered second in 
importance, only surpassed by survival [80]. Learning, attention and memory are all cognitive 
functions that might be affected, which potentially could influence the patient's quality of life. 
Pediatric patients are of particular risk of suffering from cognitive impairment as their brain 
develops rapidly at young age. Also, pediatrics have a greater degree of so-called myelination 
of white matter tracts and a higher degree of neurogenesis compared to adults which may play 
a role [81]. Both the radiation dose and volume of irradiation are suggested to have an impact 
on cognitive outcomes [82, 83]. The comparative physical advantages of protons over photons 
might limit the cognitive side effects, due to less damage to normal tissue.  
5.1 Radiation-induced cognitive brain damage 
The brain tissue can be divided into two components; grey and white matter. Structural brain 
changes in these two components have been related to a broad variety of neurocognitive 
outcomes [84]. White matter is vital in linking several elements of grey matter together. Myelin, 
which is produced in the oligodendrocytes, is essential in signaling transmission. 
Oligodendrocytes form and preserve myelin, which surrounds white matter axons, as seen in 
Figure 5.1 [85]. Radiation causes oligodendrocytes depletion, which results in demyelinated 
axons. In addition, impairment in white matter microvessels might damage the astrocytes, 
which provides functional support to neurons [85]. The demyelination and impairment in white 
matter microvessels are presumed to be roots of white matter damage. Peiffer et al. suggested 
a neuroanatomical target theory based on the assumption that selective damage to specific 
targets may result in cognitive impairment [86]. The neural stem cell number is considerably 




Figure 5.1: Illustration of radiation-induced white matter damage [85]. As seen in this figure, the 
radiation causes oligodendrocytes depletion which demyelinates the axons. 
5.2 Published models used to estimate change in 
intelligence quotient score 
When assessing the general neurocognitive functioning of patients undergoing brain tumor 
treatment, the full-scale intelligence quotient (FSIQ) is commonly used [87]. This measure 
labels several intellectual skills, i. e. working memory, processing speed, verbal 
comprehension, and perceptual reasoning. In clinical settings, estimated intelligence quotient 
(IQ) is also commonly used. However, the estimated IQ does not take into account the 
processing speed, which is one of the main contributors to the decline estimate in FSIQ for 
pediatric brain tumor patients [87].  
There have been multiple previous attempts to model the effect of radiation therapy treatment 
on IQ scores [10, 19, 21, 88]. A prior study found that patients receiving > 43.2 Gy to a threshold 
volume of 13 % to the left temporal lobe were of particular risk of experiencing a decline of 
more than 10 % in FSIQ score.  
Merchant et al. endeavored to model the outcome of treatment dosimetry on IQ score, based on 
a group of central nervous system (CNS) embryonal tumor patients [19]. The patients in this 
study were treated with craniospinal irradiation and conformal primary-site irradiation. From 
this study, several models were proposed, both dose/volume intervals and mean dose to five 
different volumes of brain tissue, i.e., total brain volume, supratentorial brain, infratentorial 
brain, left temporal lobe and right temporal lobe.   
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Conceptually similar IQ score models, utilizing similar methods as the previously mentioned 
study, was suggested by two studies by Merchant et al. [10, 88]. One of these studies was based 
on pediatric craniopharyngioma patients receiving conformal photon radiation therapy [88]. 
From the suggested models by this study, three partitions of dose intervals (low, intermediate, 
and high) to the total brain, supratentorial brain, and left temporal lobe could be used to estimate 
IQ scores. The other study compared the clinical advantages of proton over photon therapy in 
terms of IQ decline [10]. In this study, 10 of 40 patients were pediatric patients with 
craniopharyngioma. The group modeled a craniopharyngioma-specific model, which estimates 
the IQ score with respect to radiation mean dose to the supratentorial brain. Further explanation 
of these models will be given in methods sub-chapter 6.5.2. 
5.3 Endpoint-specific cognitive impairment  
When investigating cognitive impairment, it is furthermore relevant to look at more specific 
endpoints beyond the more comprehensive IQ measure. Pulsifer et al. indicated that the IQ 
score in pediatric patients receiving proton therapy treatment remained stable up to three years 
after treatment; however, the processing of speed was negatively affected [11]. A more recent 
study by the same group also reported considerable impairment in processing speed, in addition 
to a small negative change in IQ score [89]. Results of domain-specific impairment may 
potentially stress an underestimation of cognitive impairment if exclusive use of IQ score is 
used [87].  
Substructures are connected to cognitive abilities in various ways. Recent studies have 
investigated the association between smaller substructures and cognitive decline. For instance, 
Redmond et al. demonstrated a significant correlation between the mean dose to the 
hippocampus and the decline in some neurocognitive skills [90]. Zureick et al. suggested that 
the radiation dose to the left hippocampus might lead to more cognitive impairment in terms of 
memory score than the left temporal lobe [23]. Zureick et al. modeled the dosimetric correlation 
of verbal and visual memory outcomes after proton radiation treatment for pediatric brain tumor 
patients. The hippocampus structures are connected to learning and memory domains and are 
suggested to be particularly sensitive to radiation [91]. Preservation of these structures might 




6 Materials and methods 
6.1 Patient data 
Ten anonymized pediatric patients with craniopharyngioma, previously treated at the 
University of Florida Health Proton Therapy Institute (UFHPTI), were included in this thesis. 
Intensity-modulated proton therapy (IMPT) plans with a three-field beam configuration 
optimized with RBE 1.1 were available for the set of patients, identical to the setup of the double 
scattering proton plans (DSPT) they were treated with. The beam set-up and dose distribution 
are illustrated in Figure 6.1. The clinically delivered DSPT plans typically used a right and left 
superior anterior oblique fields as well as a superior posterior oblique field [13]. The prescribed 
dose to the tumor volume was 54 Gy(RBE) with a constant RBE of 1.1 in 30 fractions. The 
clinically approved structure sets were used for treatment planning, while BCSs (identified and 
defined by Toussaint et al. [81]) were originally delineated from the registered CT- and T1/T2 
MRI-scans. The delineated BSCs are illustrated in Figure 6.2 and listed in Table 6.1, and are 
categorized into structure subgroups, as in the publications by Toussaint et al. [13, 81]. The 
median (range) primary planning target volume (PTV) was 31 cm3 [18 – 63] across all patients.  
Table 6.1: BSCs analyzed in this thesis categorized into structure subgroups (left column). The column 
to the right shows the median and corresponding range of the volume of each BSC [13, 81].  
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Figure 6.1: RBE-weighted dose (RBE = 1.1) distributions for the patient with a target volume closest 
to the median value. CTV is shown in yellow and temporal lobes are shown in pink for a), whereas the 
CTV is shown in orange for b) and c). Panel b) illustrates the right and left superior anterior oblique 
field whereas c) illustrates the superior posterior oblique field. The dose bar in panel c) is shared by both 









     
Figure 6.2: Frontal (left column), transversal (middle column), and sagittal (right column) slice view of 
the delineated BSCs. The temporal substructures are shown in a), the ventricular substructures are shown 
in b), and the supratentorial brain substructures are shown in c). d) shows the cerebellum, Circuit of 
Papez and the supratentorial brain. The slices were chosen to best illustrate the position and volume of 




6.2 Monte Carlo simulations 
The LET and the dose distributions from variable RBE models were calculated on the planning 
CT using the FLUKA MC code together with its interface, FLAIR [93, 94]. Through in-house 
python scripts provided by Fjæra (2016) [95], the treatment plan data was converted into 
FLUKA-input files. The scoring files from the simulation, which contains the dose and LETd 
data, were converted to Digital Imaging and Communications in Medicine (DICOM)-format. 
The DICOM files were further imported to the Eclipse treatment planning system (Varian 
Medical Systems, Palo Alto, CA, USA), and the biological dose from the variable RBE models 
were calculated. 
For all of the tissue-dependent models, with the exception of CHD, (α/β)x of both 2 and 3 Gy 
were applied in order to reflect a probable range of (α/β)x values reported in the brain [6, 7]. 
For the CHD model, (α/β)x of 1.83 Gy and 8.71 Gy were used, as this model is derived from 
separate fits to two different cell lines with (α/β)x values corresponding to the two input 
parameters used. In terms of the non-tissue dependent models, we applied a constant (α/β)x of 
3.76 Gy for the WIL model and a constant (α/β)x of 3.33 Gy for the CHE model. The input 
parameter of 3.76 Gy applied to the WIL model is the ratio of the intermediate value of αx and 
βx in the V79 cell line found by Tilly et al. [96]. An in-house script was used to extract data 
from dose-volume histograms in Eclipse. 
6.3 Model selection 
The variable RBE models differ from each other in terms of assumption, regression technique, 
and database [8]. Key values in the experimental database are found in Table 7.1 along with the 
abbreviations used in this thesis, whereas the mathematical formulation of each model is shown 
in Appendix A. A more extensive comparison of the models is found in Rørvik et al. [76]. A 
set of selection criteria was defined to identify the most suitable models for the endpoint of 
cognitive impairment to brain tissue while also covering relevant LET values. In addition we 
set a lower limit for data points used to fit each model. The criteria were: 
 Range of radiation fractionation sensitivity (α/β)x data point values covering 2 – 3 Gy, 
which reflects the probable range in BSCs [6, 7]. 
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 LETd data point values covering a range up to 20 keV µm
-1. The cut-off value mirrors 
clinically relevant LETd values. 
  > 20 data points in the experimental database.  
In order to demonstrate how the range of RBE estimates differed between models fulfilling the 
selection criteria as compared to the full model collection, all models (summarized in Table 
7.1) were also applied to one of the patients. Two additional plan-based models were also used; 
FRE and UNK. 
6.4 Relative biological effectiveness 
Discrete RBE values for each structure were calculated by dividing the mean physical dose by 
the RBE-weighted mean dose from each model. The equation for the dose-weighted mean RBE 
(RBEd) is shown below: 
RBEd = 
Physical mean dose (Gy)
RBE−weighted mean dose (Gy(RBE))
     (6.1) 
First, we analyzed the RBEd across all BSCs for all variable RBE models mentioned in section 
4.3.2. This was done for the patient with target volume closest to the median value. We analyzed 
how the variable RBE models differed in terms of RBEd value across all BSCs and estimated a 
potential range of RBEd within each BSC according to all variable RBE model. 
Further, we analyzed RBEd values with a selected set of models chosen from the method 
explained in section 6.3. In order to evaluate to which extent the estimated range of RBEd 
differed across the selected models and all models, we calculated the range across all BSCs for 
the selected set of models for the same patient, which all models were applied to. We further 
applied the selected set of variable RBE models to the full patient cohort and evaluated the 
differences between patients, BSCs and variable RBE models.  
6.5 Cognitive impairment 
We investigated the fraction of volume receiving 10 and 40 Gy(RBE) for their association with 
white matter damage (%V40Gy) and reduction of neural stem cell number (%V10Gy) from 
data extracted from DVHs [86]. The two dose/volume parameters were first analyzed across all 
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variable RBE models for the patient with the target volume closest to the median value. Further, 
we analyzed the dose/volume parameters across all patients for the selected set of models.  
6.5.1 Estimated endpoint-specific cognitive decline 
The risk of memory impairment was calculated by a model proposed by Blomstrand et al. [97] 
(Eq. 6.13), which is fitted to odds ratios of memory impairment at different temporal doses 
published by Armstrong et al. [22]. Toussaint et al. derived the proposed model to better match 
the function with craniopharyngioma patients [13, 22]. The model calculates the risk of 
impairment, pd, using the odds ratio at 10 Gy, OR10, the baseline risk of memory impairment at 
zero dose, po, and the dose to the temporal lobe, d. The values used for OR10 and po are 1.14 
and 0.246, respectively. 
Zureick et al. proposed a model for memory impairment after radiation therapy with protons, 
based on the dose to the left hippocampus [17] (Eq. 6.14). This model correlates the volume of 
the left hippocampus receiving 20 Gy to delayed verbal memory (DVeM) score at a time, t, 
after radiation therapy. The covariates (age = 7, sex = female, neurological symptoms at 
baseline) used in this thesis are the same as in another publication based on the same patient 
group [13]. These values were set to constant across the whole patient group to observe the 
specific impact of dose and RBE on the memory score estimates. We calculated the DVeM 
score 24 months after radiation therapy and compared the score to the baseline value.  
6.5.2 Estimated IQ score decline 
A total number of ten equations from three publications from Merchant et al. were used to 
estimate the change in IQ score after radiation therapy treatment (Eq. (6.2 - 6.11) in Table 6.2) 
[10, 19, 88]. Of these, six models were based on patient age at radiation therapy treatment and 
fraction of volume of the brain, supratentorial brain, and left temporal lobe receiving doses in 
low, intermediate, and high dose/volume intervals. The four remaining models were based on 
the patient age at radiation therapy treatment and the mean doses to the same brain volumes as 
above. The IQ models were rewritten to estimate the change in IQ compared to the baseline 24 
months after radiation therapy treatment.  
Merchant et al., hereby referred to as CNS models, developed both dose/volume interval and 
mean dose IQ score models (Eq. 6.5 – 6.10) [98]. We utilized both approaches and compared 
32 
 
the results. Both 2 - and 3-term equations were suggested for the whole brain and supratentorial 
dose/volume interval models. The 3-dose-interval models were chosen for this thesis as the high 
dose-interval was considered to have a significantly more adverse effect than the other intervals. 
Three other dose/volume interval models by Merchant et al. were used (Eq. 6.2 – 6.4). These 
models are hereby referred to as craniopharyngioma models. Also, one model based on the 
mean dose to the supratentorial brain by Merchant et al. was used to estimate the decline in IQ 
score (Eq. 6.11). This model is derived from patients receiving proton therapy and is hereby 
referred to as the craniopharyngioma proton model. The proposed threshold of 13 % of the left 
temporal lobe volume receiving 43.2 Gy proposed by Jalali et al. was also investigated.  
Table 6.2: Models used to estimate cognitive impairment, listed by year of publication. The column to 
the far right shows the corresponding number of each equation. For equation 6.2 – 6.10, time (t) is 
measured in months, mean dose is measured in Gy, and the volume terms represent the fraction of 
volume which receives the dose over the specified interval. For equation 6.14, time (t) is measured in 
years. Abbreviations: L = left, Temp. = Temporal, Supra = Supratentorial  





IQchange = (−0.0044 x V0−25 Gy + 0.0313 x V25−45 Gy − 0.0253 x V45−60 Gy) x t 
IQchange = (−0.00401 x V0−30 Gy + 0.0464 x V30−45 Gy − 0.0278 x V45−60 Gy) x t  
IQchange = (−0.00415 x V0−30 Gy + 0.0155 x V30−45 Gy − 0.0127 x V45−60 Gy ) x t 
Brain 
Supra Brain 








al. 2006b IQchange = (−0.41x V20−35 Gy − 0.43 x V35−65 Gy − 0.36 x V45−65 Gy ) x t 
IQchange = (−0.38 x  V20−30 Gy − 0.31 x V30−55 Gy − 1.37 x V55−65 Gy ) x t 
IQchange = (−0.40 x  V15−40 Gy − 0.44 x V40−65 Gy ) x t 
IQchange = (−0.0095 x Mean Dose) x t 
IQchange = (−0.0091 x Mean Dose) x t 
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6.5.3 Statistical analysis 
In terms of the statistical uncertainties for the FLUKA MC code, the uncertainty decrease with 
1/√N, where N is the number of particles. Each field was simulated separately for every patient, 
and two simulation cycles with 2.5x107 primaries were used for each subscribed field. 
Wilcoxon signed-rank tests for paired samples were used to analyze the relationship between 
RBE 1.1 and proton RBE models in terms of IQ score. In addition, we evaluated if the different 
IQ score models within each publication differed significantly from each other. The Wilcoxon 
signed-rank test is commonly used to compare paired data when the data is not assumed 
normally distributed [99]. A p-value < 0.05 were considered significant. In order to evaluate 
statistical significance, the absolute value of the difference between two groups of data from 
lowest to highest were ranked, where the lowest difference between the values ranks 1. The test 
statistics, W, is the sum of ranks for positive or negative differences and is given by the equation 
below:  
 W = ∑ ZiRi
n
i=1       (6.15) 
where Ri is the rank and Zi is an indicator of a positive or negative value. The standard deviation, 




      (6.16) 
                 μw =
n(n+1)
4
        (6.17) 
where n is the total number of observations. For n ≥ 10, the unit of normal distribution, z, can 
be calculated directly as seen in the equation below:  
                 z =  
W−μw
σw
       (6.18) 
We further obtained the p-values using a two-tailed test. The equation used for the p-value is 
shown below: 




Chapter 7.1 shows the results from the model selection method explained in chapter 6.3. 
Further, chapter 7.2 presents results for the one patient where all RBE models were utilized, 
and chapter 7.3 presents the results across all ten patients.  
7.1 Model selection  
Among the eleven phenomenological models, five fulfilled the criterion for data points, four 
for (α/β)x  and five for LETd, as seen in Table 7.1. Four models (CHE, TIL, WED, WIL) failed 
on all criteria, whereas two models failed on two (PLR, MAI), and two models (CAR, CHD) 
failed by one criterion. The two plan-based models, UNK and FRE, were excluded as these are 
not fitted to in vitro data. The models selected for further calculations of risk of cognitive 
impairment, still accounting for variable biological effectiveness, were the models by ROR, 
MCN, and JON. The weighted version (RORW) of the ROR models was chosen for the set of 
models as experiments of high quality are weighted more in regression analysis. 
Table 7.1: Overview of data point values in experimental databases used to fit the variable RBE models 
along with model dependencies. Cut-off values of the criteria are given in parenthesis. Numbers in bold 








(α/β)x range [Gy] 
(2 – 3) 
LETd range 
[keV µm-1] 
(Up to 20) 
Depend 
-encies 
Carabe et al (2012) [74] CAR 44 2.0 – 2.8 1.0 – 20.0 LETd, (α/β)x 
Chaudary et al (2014) [64] CHD 12 1.8 – 22.7 1.1 – 25.9 LETd, (α/β)x 
Chen and Ahmad (2012) [65] CHE 14 2.2 – 2.8 7.7 – 37.8 LETd 
Jones (2015) [67] JON 28 0.5 - ∞ 0.5 - 33-0 LETd, αx, βx 
Mairani et al (2017) [75]  MAI 25 7.7 – 37.8 2.7-69.5 LETd, (α/β)x 
McNamara et al (2015) [71] MCN 285 0.1 – 29.5 0.2 – 20.0 LETd, (α/β)x 
Peeler (2016) [68] PLR 48 2.6 – 5.1 0.9 – 19.0 LETd, (α/β)x 
Rørvik et al (2017) [66] RORW/RORUW 85 1.2 – 18.4 0.4 – 37.8 d(L), (α/β)x/LETd, 
(α/β)x 
Tilly et al (2005) [69] TIL 7 2.7 – 2.8 7.7 – 20.0 LETd, (α/β)x 
Wedenberg et al (2013) [70] WED 19 2.7 – 69.5 7.7 – 30.0 LETd, (α/β)x 




7.2 Relative biological effectiveness and dose/volume 
parameter estimation across all models 
Across the thirteen different variable RBE models, there were significant variations in RBE-
weighted doses and RBE in the BSCs in the selected patient, as seen in Figure 7.1. The large 
variations can also be seen in Figure 7.2, where RBE distribution for all variable RBE models 
is shown. Only the PLR model estimated RBEd to be less than 1.1 consistently across all BSCs. 
All BSCs considered, the lowest (1.14) and highest (1.65) median RBEd across all variable RBE 
models were observed for the left parietal lobe and cerebellum, respectively. The corresponding 
RBEd ranges across all models were 0.82 – 1.29 for the left parietal lobe and 0.85 – 2.26 for the 
cerebellum structure. The CHE model provided the highest values of RBEd across all structures 
apart from the cerebellum, parietal lobes, and left hippocampus tail, where the unweighted 
version of the ROR model provided the highest values. The model by PLR systematically 
resulted in the lowest RBEd values.  
 
 
Figure 7.1: Scatter plot of the calculated RBEd of the analyzed BSCs across all models. The horizontal 
solid line shows RBE of 1.1. Open and closed symbols indicate (α/β)x of 2 and 3 Gy, respectively. 
Abbreviations: Ent. Cor. = Entorhinal Cortex, L = left, R = right, LFWM = Left frontal white matter, 






Figure 7.2: RBE distribution for all variable RBE model used in the thesis. The number following each 





All RBEd values within each structure subgroup for all variable RBE models for the selected 
patients are included in Appendix B. In Figure 7.3, the LETd for the selected patient is shown 
along with delineation of the temporal lobes. The temporal lobe substructures resulted in a 
higher median RBEd than the supratentorial and ventricular substructures for all variable RBE 
models. Table 7.2 presents median RBEd across all BSCs and median RBEd within each 
structure subgroup for all variable RBE models. As seen in Table 7.2, three models (PLR, FRE, 
and UNK) estimated a lower median RBEd across all BSCs than 1.1. 
 
Figure 7.3: LETd distributions for the patient with target volume closest to the median value. The 
delineated volumes are CTV (yellow) and temporal lobes (pink). 
Table 7.2: Median RBEd across all BSCs (second column) and median RBEd values with range in 
brackets across different structure subgroups (three columns to the far right). The models are arranged 
by ascending order by median RBEd across all BSCs. For the tissue-dependent models, both input 












PLR 0.96 [0.81  – 1.08] 0.93 [0.81  – 1.01] 0.97 [0.92 – 1.03] 1.01 [0.84 – 1.08] 
FRE 1.07 [1.02  – 1.37] 1.05 [1.03 – 1.08]  1.05 [1.04 – 1.08] 1.08 [1.05 – 1.12] 
UNK 1.09 [1.04  – 1.22] 1.08 [1.05 – 1.11] 1.11 [1.10 – 1.17] 1.11 [1.09 – 1.14] 
CHD 1.14 [1.09 – 1.59] 1.12 [1.10 – 1.22] 1.11 [1.10 – 1.17] 1.17 [1.11 – 1.22] 
TIL 1.16 [1.08  – 1.41] 1.13 [1.09 – 1.28] 1.14 [1.10 – 1.23] 1.21 [1.13 – 1.36] 
CAR 1.17 [1.01  – 1.91] 1.13 [1.01 – 1.23] 1.14 [1.07 – 1.22] 1.21 [1.14 – 1.29] 
WIL 1.20 [1.09  – 1.84] 1.17 [1.09 – 1.22] 1.13 [1.12 – 1.21] 1.24 [1.16 – 1.29] 
RORW 1.20 [1.14  – 1.83] 1.20 [1.15 – 1.28] 1.18 [1.15 – 1.22] 1.22 [1.14 – 1.34] 
MCN 1.21 [1.12  – 1.90] 1.18 [1.12 – 1.26] 1.19 [1.15 – 1.24] 1.24 [1.17 – 1.33] 
WED 1.24 [1.14  – 2.09] 1.20 [1.14 – 1.29] 1.19 [1.16 – 1.24] 1.26 [1.16 – 1.39] 
MAI 1.26 [1.18  – 2.01] 1.24 [1.21 – 1.31] 1.22 [1.20  – 1.28] 1.29 [1.18  – 1.40] 
JON 1.27 [1.18  – 2.23] 1.24 [1.18 – 1.31] 1.21 [1.19 – 1.29] 1.33 [1.20 – 1.42] 
RORUW 1.32 [1.21  – 2.43] 1.32 [1.21 – 1.43] 1.28 [1.22 – 1.35] 1.38 [1.23 – 1.57] 




In terms of the three selected models (JON, MCN, and RORW), the JON model provided the 
highest median RBEd value, whereas RORW resulted in the lowest for the selected patient. As 
seen in Figure 7.4, the estimated RBEd range across the investigated structures from the three 
selected models was narrower and thereby more consistent as compared to the RBEd estimates 
from the excluded models. The median RBEd (range in brackets) across all models and 
structures for the one patient was 1.20 [0.81, 2.61], whereas it was 1.22 [1.12, 2.23] for the 
selected set of models. 
 
 
Figure 7.4: Illustration of minimum and maximum RBEd values for all models (filled green) and the 
selected set of models (filled yellow) calculated for the patient with target volume closest to the median 
value. Both input parameters of (α/β)x were applied to the tissue-dependent models. The beige bars show 
the physical mean dose of each structure. Black dashed line show RBE 1.1, and the two other dashed 
lines show median values across all structures for all models (green) and the selected set (yellow). 
Abbreviations: Ent. Cor. = Entorhinal Cortex, L = left, R = right, LFWM = Left frontal white matter, 







Following the results for the RBEd estimates, large variations were also seen in the dose/volume 
parameter (%V10Gy and %V40Gy). Figure 7.5 shows DVH for the left hippocampus head for 
all variable models for the selected patient. Estimates for the left hippocampus head resulted in 
the most extensive range across all variable RBE models in %V40 Gy(RBE) [38 – 90%]. The 
corpus callosum showed the largest range across all models in %V10 Gy(RBE) [42 – 65%].  
 
 
Figure 7.5: DVH of the left hippocampus head, which showed the largest difference across all models 
for %V40Gy(RBE). The number following each model represents the input parameter of (α/β)x. Solid 
and dashed lines indicate (α/β)x of 2 and 3 Gy, respectively. The non-tissue dependent models are all 
represented by solid lines.  
Figure 7.6 presents the fraction of BSC volume receiving 10 and 40 Gy(RBE). Interestingly, 
the RORUW model presented the highest volumes receiving 10 Gy(RBE) for all structures, 
whereas the CHE model provided the highest RBEd values and highest volume receiving 40 
Gy(RBE) across all structures. PLR systematically resulted in the lowest values for both 





Figure 7.6: Fraction of BSC volume receiving 10 Gy(RBE) (upper) and 40 Gy(RBE) (lower) across all 
variable RBE models used in this thesis. The number following each model represents the input 
parameter of (α/β)x. Abbreviations: Ent. Cor. = Entorhinal Cortex, L = left, R = right, LFWM = Left 
frontal white matter, Hippo = Hippocampus, SVZ = Subventricular zone 
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7.3 Results across the selected set of models 
7.3.1 Relative biological effectiveness and dose/volume parameter 
estimation across the selected set of models 
Considering only the selected models (JON, MCN and RORW), the estimated RBEd range 
across all the studied BSCs and patients was 1.11 - 3.31. RBEd values across both input 
parameters of (α/β)x  (2 and 3 Gy) for each model along with the median physical dose across 
all patients are presented in Figure 7.7. The JON model estimated the highest median RBEd at 
1.30 [1.15 – 3.31] across all structures and patients, whereas the RORW and MCN models 
resulted in median values of 1.22 [1.12 – 2.46] and 1.23 [1.11 – 2.62], respectively.  
 
 
Figure 7.7: RBEd values of the studied BSCs, arranged in ascending order by the median physical mean 
dose (yellow bars) across all patients and both input parameters of (α/β)x. The horizontal dashed lines 
represents the median values for JON (green), MCN (red) and RORW (blue) across all BSCs. The box 
attaches the inner two quartiles, while the line in the middle of the box represents the median value to 
each BSC. Abbreviations Ent. Cor. = Entorhinal Cortex, L = left, R = right, LFWM = Left frontal white 




Following the results from all models, estimates of the cerebellum structure resulted in the 
highest median RBEd value of 1.79 [1.39 – 2.61] across all patients also for the selected models. 
As seen in the previous figure (Fig. 7.7), the cerebellum structure were, however, exposed to 
low physical doses. The estimated median RBEd for the anterior part of the cerebellum was 1.69 
[1.36 – 2.48], whereas the median RBEd for the posterior part was 2.11 [1.56 – 3.31] across the 
selected models. The structure with the lowest range across all patients for the selected set of 
models was the right frontal lobe, with RBEd ranging from 1.14 – 1.25. Compared to other 
BSCs, the estimated RBEd were low for both the frontal and parietal lobes. 
 
A comparison of the RBE distributions for (α/β)x of both 2 and 3 Gy for JON, MCN and RORW 
is shown in Figure 7.8. As seen in this figure, RORW and MCN resulted in higher RBE with 
decreasing (α/β)x, whereas the opposite trend was shown for JON. Across the three selected 
models, the median RBEd was 1.26 [1.41, 3.11] and 1.22 [1.11, 3.11] for (α/β)x of 2 and 3 Gy, 
respectively. 
 
The estimated RBEd for both (α/β)x of 2 and 3 Gy across all BSCs are presented in Figure 7.9. 
As seen in this figure, the difference in RBEd values from the two (α/β)x input parameters was 
less prominent for the JON model than for RORW and MCN. Across all BSCs for the full 
patient cohort, the JON model estimated a median value of 1.29 [1.15, 3.31] and 1.31 [1.16, 
3.1] for (α/β)x of 2 and 3 Gy, respectively. The difference in the median value was larger for 
MCN and RORW, as seen in Figure 7.9. For the MCN model, the estimated median value was 
1.26 [1.15, 2.62] for 2 Gy and 1.20 [1.11, 2.11] for 3 Gy as input parameter of (α/β)x. For 
RORW, the estimated median value was 1.24 [1.15, 2.46] and 1.19 [1.11, 2.01] for (α/β)x of 2 
and 3 Gy, respectively. 
 
The estimated RBEd range between (α/β)x of 2 Gy and 3 Gy for MCN and RORW appeared to 
be lower for BSCs generally exposed to high dose levels, e.g., amygdala, thalamus, and 






Figure 7.8: RBE distributions for the models by RORW (a), MCN (b), and JON (c) with both (α/β)x  of 
2 (left) and 3 Gy (middle) as input parameter. The column to the right illustrates the difference in RBE 






Figure 7.9: RBEd values of the studied BSCs for the two input parameters of (α/β)x for the RORW 
(upper), JON (middle) and MCN (lower) models. Green boxes and points indicate (α/β)x of 2 Gy, 
whereas the red boxes and points indicate (α/β)x of 3 Gy. The horizontal dashed lines represent the 
median value for (α/β)x of 2 (green) and 3 Gy (red) across all BSCs, and the black horizontal dashed line 
represents RBE 1.1. The box attaches the inner two quartiles, while the line in the middle of the box 
represents the median value to each BSC. Abbreviations: Ent. Cor. = Entorhinal Cortex, L = left, R = 
right, LFWM = Left frontal white matter, Hippo = Hippocampus, SVZ = Subventricular zone 
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A comparison of the calculated RBEd values within each structure subgroups are presented in 
Figure 7.10 & 7.11. Figure 7.10 also shows the inter-patient differences between the estimated 
RBEd values. As seen in Figure 7.10, JON provided the highest values for the RBEd across all 
structures and patients except the parietal lobes, where the model by RORW provided the 
highest values for some patients. JON estimated higher RBEd values with an (α/β)x of 2 Gy 
compared to 3 Gy for this structure. For the JON model, this trend only appeared for the parietal 
lobes and some patient cases in the cingulum structure.  
 
Among the supratentorial structures, the highest RBEd values were found in the temporal lobes, 
with a median RBEd across the selected set of models of 1.27 [1.18 – 1.45] and 1.26 [1.16 – 
1.41] for the left and right, respectively. Compared to the parietal and frontal lobes, estimates 
for the thalamus structure resulted in high RBEd values with a median value of 1.22 [1.15 – 
1.31] (left) and 1.20 [1.14 – 1.31] (right).  
 
As seen in Figure 7.11, all the selected models estimated high RBEd values for the temporal 
lobe BSCs when compared to the other structure subgroups. The amygdala and entorhinal 
cortex were in addition exposed to the high physical dose. The highest RBEd values were found 
in the hippocampus structures, where estimates of RBEd for the left hippocampus tail resulted 
in a median value of 1.41 [1.17 – 2.21] across all patients.  
 
Estimates of the RBEd for the left and right cingulum resulted in the highest RBEd amid the 





Figure 7.10: RBEd values for the selected set of models for the supratentorial brain substructures 
(upper), temporal lobe substructures (middle) and ventricular substructures (lower). The black 
horizontal dashed line show RBE 1.1. Horizontal lines associated to each structure shows the median 
value across all patients of the RBEd from selected models, with solid lines representing (α/β)x = 2 Gy 
and dashed line shows (α/β)x = 3 Gy. Green lines show median values of JON, yellow lines illustrate 
the median values of ROR and median values from the MCN model are shown in red. Patients are sorted 
in ascending order by CTV volume. Abbreviations: Ent. Cor. = Entorhinal Cortex, Front = Frontal, L = 






Figure 7.11: RBEd values for the selected set of models in the supratentorial substructures (upper), 
temporal lobe substructures (middle), and ventricular substructures (lower). The box attaches the inner 
two quartiles, while the line in the middle of the box represents the median value. Abbreviations: Corp. 
= Corpus, Ent. Cor. = Entorhinal Cortex, Front = Frontal, L = left, R = right, Par = Parietal, Temp = 
Temporal, SVZ = Subventricular zone. 
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Figure 7.12 shows a DVH of the right thalamus. Estimates for the thalamus resulted in the 
highest variation between all patients for the studied dose/volume parameters, all models 
considered. Across all patients, the estimated range for the right thalamus was 41% - 100 and 
2% – 93% for %V10Gy(RBE) and %V40Gy(RBE), respectively.  
 
Figure 7.12: DVH of the right thalamus for the full patient cohort for the JON model with 2 Gy as input 
parameter of (α/β)x, illustrating the large inter-patient differences found for %V10 and %V40 Gy(RBE) 
for this structure. The patients are sorted in ascending order by CTV, and the number following the 
model name in the legend indicates the patient number. 
The estimated range in dose/volume parameters was considerably narrower for the set of 
models within each patient compared to the range across all models; however, considerable 
variations were seen between patients, as seen in Figure 7.13 & 7.14. Median value and 
corresponding range across all patients for the two dose/volume parameters for the set of models 
are presented in Appendix C. As with the RBEd calculation, the RORW model led to the highest 
median values of %V10Gy(RBE) for the parietal lobes. None of the models from the selected 
set presented a lower volume than the RBE-weighted dose of 1.1 for any of the structures within 
the two studied dose/volume parameters. Especially for the %V40Gy(RBE) parameter, the 
variable RBE models resulted in considerably higher volumes than RBE-weighted dose of 1.1. 
In terms of target volume dependency, a higher volume of the BSCs receiving 10 and 40 
Gy(RBE) was generally observed in patients with large target volume. The correlation 
coefficient of median volume across all structures for %V10Gy(RBE) and %V40Gy(RBE) was 




Figure 7.13: Fraction of BSC volume receiving 10 Gy(RBE) across the selected set of variable RBE 
models for the full patient cohort. The number following each model represents the input parameter of 
(α/β)x. The number to the far left shows the patient number. The patients are sorted in ascending order 
by CTV volume. Abbreviations: L = left, R = right, Ent. Cor. = Entorhinal Cortex, Hippo = 




Figure 7.14: Fraction of BSC volume receiving 40 Gy(RBE) across the selected set of variable RBE 
models for the full patient cohort. The number following each model represents the input parameter of 
(α/β)x. The number to the far left shows the patient number. The patients are sorted in ascending order 
by CTV volume. Abbreviations: L = left, R = right, Ent. Cor. = Entorhinal Cortex, Hippo = 
Hippocampus, LFWM = Left frontal white matter, SVZ = Subventricular zone 
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7.3.2 Estimated cognitive impairment 
The current sub-chapter will present the results of the estimated cognitive impairment. The 
results are summarized in Table 7.3, whereas discrete values are found in Appendix D. In 
general, variable RBE models which led to the highest values of RBEd, also reported a higher 
estimated IQ score decline, a higher decline in DVeM score and a higher risk of memory 
impairment compared to RBE 1.1. DVHs comparing the different variable RBE models to RBE 
1.1 for the brain volumes used to estimate cognitive impairment are shown in Figure 7.15.  
 
Figure 7.15: DVHs of the brain volumes used to estimate cognitive impairment for the patient with a 
target volume closest to the median value. Solid and dashed lines indicate (α/β)x of 2 and 3 Gy, 





All utilized IQ models estimated a decline in IQ scores, as seen in Figure 7.16 & 7.17. However, 
the results varied significantly across the models from the three different publications. At 24 
months after radiation therapy, the median and range across all IQ score models for the set of 
proton RBE models was -1.7 [-10, 0.0]. For each variable RBE model, the median was -1.9 [-
9.3, 0.0] for JON, -1.8 [-9.9, 0] for RORW, and -1.8 [-10, 0.0] for MCN. For RBE 1.1, the 
median was -1.6 [-9.5, 0.0]. The craniopharyngioma proton model indicated the lowest values 
in IQ change of the IQ models. The estimated IQ score change was close to zero across all the 
selected proton RBE models and RBE 1.1 for all patients.  
The median IQ score change across all CNS models (Eq. 6.5 – 6.10) was -1.6 [-3.4, -0.7] 
considering all the selected variable RBE models (Fig. 7.16). Interestingly, the CNS models 
presented significantly different results for the two IQ estimate approaches (mean dose and 
dose/volume interval) for RBE 1.1. When comparing the two approaches across the selected 
models, a significant difference was seen for the brain and left temporal lobe volume, whereas 
the difference in the supratentorial brain volume model was not significant at the p = 0.05 level 
for any of the variable RBE models. Overall, the median value of the IQ score decline was 
lower with the dose/volume interval models. Across all variable RBE models, the median value 
of the change in IQ score was -1.5 [-3.4, -0.7] for the dose/volume interval models, whereas the 
mean dose models resulted in the median value of -1.7 [-3.1, -1.2].  
Common for all CNS models was that RBE 1.1 consistently estimated lower IQ score decline 
than the selection of RBE models, as seen in Figure 7.16. Median across all models for the 
supratentorial model was -1.7 [-2.6, -1.2], -1.9 [-3.1, -1.2] for the left temporal lobe and -1.7 [-
2.6, -1.2] for the brain volume. When comparing RBE 1.1 with the selected set of models, the 
largest differences were seen for the supratentorial brain dose/volume interval model. For this 
brain volume, the median value was -0.9 [-1.8, -0.6] for RBE 1.1, and -1.7 [-3.4, -1.0] for the 
selected variable proton RBE models. In terms of target volume-dependency, patients with a 
large target volume tended to be more vulnerable to IQ decline scores for the brain – and 
supratentorial brain model, which can be observed in Figure 7.16. In terms of the two input 
parameters, the patterns were comparable to those presented in the previous section; a higher 





Figure 7.16: Estimated change in IQ scores 24 months after radiation therapy (RT) treatment calculated 
from equation (6.4 – 6.9). The upper row shows calculation from dose/volume models, whereas the 
lower row represents models based on mean dose. The patients are sorted in ascending order by CTV. 
The craniopharyngioma models (Eq. 6.2 – 6.4) resulted in the highest IQ score change of all IQ 
models with a median value of -8.9 [-10.0, -7.0] (Fig. 7.17). The trend with lower IQ score 
decline with RBE 1.1 compared to the variable RBE models seen be the CNS models were not 
seen for the craniopharyngioma models. Across all craniopharyngioma models, the median 
value was -8.1 [-9.3, -7.0] for JON, -9 [-9.9, -7.6] for RORW and -8.9 [-10, -7.2] for MCN. For 
RBE 1.1, the median was -8.9 [-9.5, -8.1]. RORW with an (α/β)x of 2 Gy as input parameter 
did not result in a statistically significant difference compared with RBE 1.1 for any of the 
craniopharyngioma models. Variations were seen across the three different craniopharyngioma 
models, and the supratentorial brain model differed significantly from both the other models. 
The model based on the brain dose/volume intervals estimated the largest change with a median 
value of -9.1 [-10, -7.0]. The left temporal lobe and supratentorial brain models resulted in a 




Figure 7.17: Estimated change in IQ scores 24 months after radiation therapy (RT) treatment calculated 
from equation (6.1 – 6.3). The patients are sorted in ascending order by CTV.  
In terms of the investigated 13 % threshold for the left temporal lobes 43.2 Gy, no values above 
13 % were found for any of the patients, as shown in Figure 7.18. However, some of the 
temporal lobe substructures, e. g. amygdala and entorhinal cortex showed values above the 
threshold across all models and patients.  
 
Figure 7.18: Volume of the left temporal lobe receiving 43.2 Gy(RBE). The patients are sorted in 
ascending order by CTV.  
Overall, elevated RBE led to a higher risk of memory impairment, as shown in Figure 7.19. At 
24 months after radiation therapy treatment, the median risk of memory impairment across the 
selected models was 40 % [34 % - 49 %], slightly higher than RBE 1.1, which resulted in the 
median value of 38 % [33 % - 45 %]. The difference in the estimated risk of memory impairment 
between the three selected models was not significant. Across all patients, the median and range 





Figure 7.19: Estimated risk of memory impairment 24 months after radiation therapy (RT) treatment 
calculated from equation (6.13). The patients are sorted in ascending order by CTV.  
Compared to the variable RBE models, changes in DVeM scaled score was consistently lower 
for RBE 1.1, as seen in Figure 7.20. The model by JON systematically resulted in the highest 
change of the selected set of models, whereas the model by RORW and MCN resulted in the 
same median value and range. Across all patients, the median changes in DVeM scaled score 
were –0.77 [-0.97, -0.58] for RBE 1.1, -0.85 [-1.02, -0.63] for JON, and -0.83 [-1.01, -0.60] for 
both RORW and MCN.  
 
Figure 7.20: Changes in delayed verbal memory scores 24 months after radiation therapy (RT) 
treatment calculated from equation (6.14). The patients are sorted by ascending order by CTV.  
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Table 7.3: This table presents the median value and corresponding range calculated from equations 6.2 
– 6.14 across all patients. Column to the far left shows the number of the equation used. The numbers 
in the cells below each variable RBE model represents the input parameter of (α/β)x. Cells colored grey 
indicate statistically significant (p < 0.05) compared to RBE 1.1 all patients considered by the Wilcoxon 
Signed-Rank Test, whereas cells colored pink indicate a trend to significance (0.05 < p < 0.1). 
#  Median [range] 
 RBE 1.1 JON MCN RORW 
Input parameter of (α/β)x 
2 3 2 3 2 3 




-9.4 [-9.5, -8.1] -8.7 [-9.3, -7.0] -8.3 [-8.9, -7.2] -9.0 [-9.5, -7.2] -9.5 [-10.0, -7.9] -9.4 [-9.9, -7.6] -9.6 [-9.9, -8.2] 
-8.8 [-9.2, -8.2] -8.2 [-8.9, -7.5] -7.7 [-8.2, -7.3] -8.5 [-9.1, -7.7] -9.0 [-9.8, -8.3] -8.9 [-9.7, -8.1] -9.0 [-9.7, -8.5] 
-9.0 [-9.5, -8.8] -8.7 [-9.1, -8.3] -8.7 [-9.0, -8.1] -8.9 [-9.2, -8.6] -9.2 [-9.4, -9.0] -9.2 [-9.4, -8.9] -9.2 [-9.6, -9.0] 







-1.1 [-1.9, -0.7] -1.2 [-2.0, -0.8] -1.2 [-2.0, -0.8] -1.2 [-2.0, -0.8] -1.1 [-1.9, -0.7] -1.2 [-2.0, -0.8] -1.1 [-2.0, -0.7] 
-0.9 [-3.3, -0.6] -1.8 [-3.4, -1.2] -1.8 [-3.3, -1.2] -1.8 [-3.1, -1.1] -1.6 [-3.2, -1.0] -1.7 [-2.9, -1.1] -1.5 [-2.9, -1.0] 
-1.5 [-2.6, -0.9] -1.7 [-3.0, -1.1] -1.8 [-3.0, -1.1] -1.7 [-3.0, -1.1] -1.6 [-2.8, -1.0] -1.8 [-3.1, -1.1] -1.6 [-2.9, -1.0] 
-1.5 [-2.3, -1.1] -1.7 [-2.6, -1.3] -1.7 [-2.6, -1.3] -1.7 [-2.5, -1.2] -1.6 [-2.4, -1.2] -1.7 [-2.5, -1.2] -1.6 [-2.4, -1.2] 
-1.5 [-2.3, -1.2] -1.7 [-2.6, -1.3] -1.8 [-2.6, -1.3] -1.7 [-2.5, -1.3] -1.6 [ -2.4,  -1.2] -1.7 [-2.5, -1.3] -1.6 [-2.4, -1.2] 
-1.7 [-2.6, -1.1] -2.0 [-3.0, -1.3] -2.0 [-3.1, -1.3] -1.9 [-2.9, -1.3] -1.8 [-2.8, -1.2] -1.9 [-2.9, -1.3] -1.8 [-2.8, -1.2] 
Merchant et al. (2008): Estimated change in IQ scores 
(6.11) 0.0 [0.0, 0.0] 0.0 [0.0, 0.0] 0.0 [0.0, 0.0] 0.0 [0.0, 0.0] 0.0 [0.0, 0.0] 0.0 [0.0, 0.0] 0.0 [0.0, 0.0] 
Jalali et al. (2010): Risk of FSIQ score decline  
(6.12) < 13 % < 13 % < 13 % < 13 % < 13 % < 13 % < 13 % 
Armstrong et al. (2010): Risk of memory impairment [%] 
(6.13) 38  [33, 45] 40  [35 , 49] 40  [35 , 49] 40  [34, 48] 39  [34, 47] 40 [34 , 48] 39  [34, 47] 
Zureick et al. (2018): Delayed verbal memory score 
(6.14) -0.77 






[-1.01,  -0.62] 
-0.82 









In this thesis, a large number of BSCs were investigated in terms of cognitive impairment and 
RBE related to proton therapy of pediatric brain tumors. The results of this project illustrated 
that estimated proton RBE values to BSCs differ considerably when a large number of variable 
RBE models are utilized. By the inclusion of several variable RBE models, some of the 
uncertainties regarding the biological effectiveness of protons can be integrated into cognitive 
decline estimates. As the concept of variable RBE is known, a range of values might better 
reflect cognitive decline estimates in proton therapy than using the universal constant of 1.1.  
 
The results of the RBEd, when applying all models, showed more variations as compared to 
using the selected models only. The criteria for further model selectivity accounted for both 
physical and biological factors by including (α/β)x and LET as selection criterion; however, the 
criteria-based method with the same cut-off values is limited to similar patient groups. In the 
case of other endpoints, e.g. tumor control, the (α/β)x cut-off values should be adjusted 
accordingly, and preferably also include (α/β)x intervals to account for the uncertainties in this 
factor which alone represents complex biological factors. Compared to the phenomenological 
models, the plan-based model by Unkelbach et al. presented lower scores for RBEd across all 
structures than the associated median RBEd values, which demonstrates the extension of tissue 
dependence, and the potential for underestimating biological effects when omitting tissue 
dependence. 
 
The cut-off value for the total number of data points was based on the assumption that models 
based on a limited set of data may be more susceptible to uncertainties. Of the excluded models, 
the CHD model was the only model that would be included in the selected set if the data point 
criterion was neglected. In addition, the relative frequency of data point values is not accounted 
for through the criteria that were set. For instance, the WIL and CAR models came short in 
terms of the cut-off value of (α/β)x; however, the models have a high frequency of data point 
values of LETd within the clinical region [73, 74, 76]. These models provided values relatively 
close to the median value for most structures across all models, and therefore including these 
would have made modest differences to the estimated biological dose and RBEd range resulting 
from the selected set of models. As most clinical LETd values are within the range of 2 – 5 keV 
µm-1 [59], the LET-range could have been set narrower. However, the outcome of the LET 
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selection criteria would not have been affected by narrowing this span of values, as most of the 
models not fulfilling the LET criterion lacked data point values in the lower region. The lack 
of datapoint values in the lower region for the CHE, TIL and WED models are accounted for 
by extrapolation from high LETd data; although, this may not be a sufficient assumption if 
regions with low LETd should be non-linear [76, 100]. 
 
The increasing RBE with decreasing (α/β)x shown in the work of Paganetti et al. [59] was 
prominent for the RORW and MCN model, as excepted [66, 71, 76]. This tendency is most 
prominent for low (α/β)x values, e.g. those utilized in this study, especially for large LETd values 
[76]. An increase of RBE with increasing (α/β)x generally appeared for the JON model. This is 
in agreement with results from Rørvik et al. [76]. Furthermore, the JON model resulted in the 
highest RBEd combined with the lowest difference between input parameters ((α/β)x of 2 and 3 
Gy). As mentioned by Rørvik et al., the model which resulted in the highest RBEd values in this 
project of the selected set, the JON model, is derived from experimental data based on heavier 
particles (e.g., helium and carbon) as well as protons. These heavier ions have, in general, 
higher RBE than protons for the same LET values [67, 76]. The presence of data from heavier 
particles in model estimation may lead to an overestimate of proton RBE. As the RBE increases 
with decreasing (α/β)x for RORW and MCN contrary to JON, the span of estimated RBE values 
would increase if a higher (α/β)x values were applied for the set of models.  
 
BSCs exposed to high doses and elevated RBEd are more vulnerable to toxicity. Compared to 
the whole temporal lobes, high mean doses and elevated RBEd was predicted in some of the 
temporal lobe substructures. This highlights the significance of variable RBE to smaller 
substructures. The amygdala and entorhinal cortex, both among the temporal lobe 
substructures, were in general exposed to high doses and predicted high RBEd values. 
 
The cerebellum has recently been suggested as a structure related to cognition [101], and both 
its posterior and anterior parts are correlated to IQ decline [20]. Even though BSCs exposed to 
high biological doses were of particular interest, low doses to the brain in pediatric patients has 
also been reported to affect intellectual development [102]. All of the cerebellum substructures 
resulted in high RBEd for all patients across all variable RBE models, combined with low 
physical doses. The cerebellum is located beneath the cerebral hemisphere and near the target 
volume. Similar to previous studies, our results support the elevated RBE in high LET-regions 
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[59], bearing in mind that both the dose- and LET dependency are likely to explain the high 
RBE values found.   
 
The supratentorial region is one of the suggested larger volumes of the brain connected to 
cognitive impairment [19]. Among the supratentorial structures, estimates of the RBEd values 
for the left and right thalamus predicted high values and were exposed to high doses. The 
parietal and frontal lobes, also among the supratentorial structures, were spared of high RBEd 
compared to other structures. These structures are located in the entrance region of the beams. 
A closer agreement across the set of models was generally seen for BSCs located in low LETd 
regions. The entrance region is generally exposed to lower LET values [59], which might 
explain the relatively low RBEd values found in the parietal and frontal lobes compared to other 
studied BSCs.   
 
In the matter of the dose/volume parameters analyzed, the most considerable difference to the 
biological dose with RBE of 1.1 was seen for the %V40Gy parameter. As no values across the 
selected set of models resulted in values below the biological dose with RBE of 1.1 for either 
%V10Gy or %V40Gy, white matter damage and higher reduction of neural stem cell numbers 
are expected to occur considering the selected variable RBE models.  
 
Significant discrepancies were seen in IQ estimates, both across IQ score models and variable 
proton RBE models. The somewhat inconsistent results of IQ decline across the utilized models 
could be explained by several reasons. Firstly, two of the publications developed models from 
3D conformal radiation therapy (photon), where the dose patterns differ considerably from 
proton treatments. The transferability of these models to proton therapy treatment, therefore, 
needs to be questioned. Due to the potential inadequacy of photon technique models in 
determining potential cognitive impairment, the results need to be interpreted with caution. In 
general, some of the volumes of brain tissue are likely to receive a smaller amount of low to 
intermediate doses, due to the higher conformity achieved by proton therapy.  
Secondly, the patient groups used in model fitting also varied between the publications. The 
number of patients used to develop the models were 10 for the craniopharyngioma proton 
model, 28 for the craniopharyngioma models, and 39 for the CNS models, which overall is a 
small number of patients in model fitting.  
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In general, both increased volume fraction and radiation dose will result in lower IQ scores 
[103]. Considering the IQ models, both low and high doses contribute to a decline in IQ scores. 
Common for most equations is that the volume which receives the highest dose has a superior 
impact on the IQ decline [97].  
In terms of the craniopharyngioma proton model, Merchant et al. demonstrated a smaller 
decline in IQ scores 24 months after radiation therapy treatment with protons compared to 
photons. However, the results for the craniopharyngioma model in this thesis indicated a 
noticeably small decline in IQ score, also when compared to results from Merchant et al. [10]. 
One significant drawback of this model is that there is no clear explanation of how the model 
was fitted.  
Of the CNS models, the supratentorial brain model was considered as the best by the authors, 
due to the level of significance of each dose/volume term in addition to the difference in 
comparative dose-effect [98].  In whole-brain irradiation cases, all of the structures are expected 
to receive more significant fractions of low to intermediate doses. Of the cohort of 39 patients, 
14 patients received whole-brain irradiation with posterior fossa boost. The temporal lobes 
might have received parts of this boost, as seen from Figure 1 in Merchant et al. [98]. 
Craniopharyngioma patients are usually treated with focal irradiation, and the temporal lobes 
are in close vicinity to the target volume. The dose distribution to the temporal lobes were 
reasonably comparable to the patients used in developing the model, whereas the dose 
distribution to the brain and supratentorial brain differed.    
The CNS models systematically resulted in higher estimates of IQ decline for the proton RBE 
models compared to RBE 1.1. This was not the case for the craniopharyngioma model, where 
RBE 1.1 estimated IQ decline above the median value for all patients. One noticeable difference 
between the CNS dose/volume models and the craniopharyngioma dose/volume models is the 
intermediate term, which has opposite signs [88, 98]. For the CNS models, all dose/volume 
interval terms are expected to have a negative impact on the IQ decline, whereas the 
intermediate-term is expected to have a positive impact on the craniopharyngioma models. This 
might be a possible explanation for the contradictory results when comparing the IQ score 
decline for the RBE 1.1 and the variable RBE models.  
The results found for the craniopharyngioma models in this thesis were comparable to those of 
Toussaint et al., who also found high values of IQ decline scores using the same models for the 
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same patient group [13]. It is unsurprising to find that there is a considerable variation between 
the IQ score models due to the dissimilarities in the patient group, treatment method, and fitting 
of the model. Considering the set of IQ-models chosen for this thesis, elevated RBE is not 
necessarily associated with a higher decline in IQ score. Obviously, linear models based on the 
mean dose will result in higher IQ decline with elevated RBE. However, the craniopharyngioma 
dose/volume models did not show a clear correlation between elevated RBE and higher decline 
in IQ score. Due to the differences in dose distribution between photons and protons, one might 
argue that the Dmean are more transferable to proton dose distributions than the dose/volume 
intervals.   
As seen from the results in section 7.3, estimates of the hippocampus resulted in elevated RBE 
for all patients. The hippocampus is located in close vicinity to the target, and the differences 
of RBE-weighted dose of 1.1 and the variable proton RBE models were expected to result in 
large variations in delayed verbal memory scores. It can be seen from the equation that the 
dose/volume term has a reasonably low impact on the overall change in delayed verbal memory 
score compared to other covariates. This might explain the small differences between the proton 
RBE models. 
The publications by Merchant et al. were based on estimated the IQ score, which, as 
aforementioned, does not include the processing of speed. Even though the volumes of the 
temporal lobe receiving 43.2 Gy were below the threshold of 13% across all variable RBE 
models for all patients, the elevated doses to the left temporal lobe according to the models still 




This study showed that there was a large and systematic model-dependent variation in RBE 
across the cognitive structures. The broad span of values of resulting RBE and dose/volume 
parameter values, especially seen by the use of all models mirrors the uncertainty associated 
with the biological effects of protons. Through a criteria-based approach, it was possible to 
select a set of models that may provide a more accurate estimate of RBE-weighted dose ranges 
to BSCs. The three selected models systematically predicted RBE and dose/volume parameter 
values above the generic RBE constant of 1.1 for all BSCs investigated. These results suggest 
that the biological dose is underestimated in the BSCs for this patient group when using the 
clinically applied RBE of 1.1. As a result of the underestimated dose, the potential cognitive 
impairment might also be underestimated. As seen in this study, the smaller cognitive 
substructures may be susceptible to elevated RBE and biological dose. It could therefore be 
beneficial to assess smaller substructures when interpreting cognitive impairment after proton 
therapy as these may provide more detailed information compared to analysis of exclusively 
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This chapter presents the mathematical formulation of the variable RBE models used in this 
thesis. All models with the exception of CHD is identical to the reformulation done by Rørvik 
et al. (2018). The CHD model is also parametrized and described as functions of RBEmin and 
RBEmax. 
In summary, CHE, CHD, MAI, ROR, TIL, WED and WIL all assume RBEmin equals 1, whereas 
CAR, JON, MCN and PLR assumes that RBEmin varies. All models with the exception of CHE, 
UNK and WIL are tissue-dependent. Of the eleven phenomenological models, all models with 
the exception of CHE, ROR and PLR assume a linear relationship of RBE as a function of 
LETd. The models are listed alphabetically.  
CAR: 
RBEmax(LETd, (α β)x⁄ ) = 0.843 +  0.154
2.686 Gy(keV μm)−1
(α β)x⁄
LETd  (A.1) 
RBEmin(LETd, (α β)x⁄ ) = 1.09 +  0.006
2.686 Gy(keV μm)−1
(α β)x⁄
LETd   (A.2) 
CHD: 
The CHD model is made of two separate fits into two different cell lines. We used both fits in 
this thesis. The U87 cell line has an approximate (α⁄β)x of 1.83 Gy, and the equation is shown 
below:  
RBEmax = αx +
0.0451(keV μm)−1
αx
LETd    (A.3) 
RBEmin = 1 
The AG01522 cell line has an approximate (α⁄β)x of 8.73 Gy, and the equation for this fit is 
shown below: 
RBEmax = αx +
0.00127(keV μm)−1
αx
LETd    (A.4) 
RBEmin = 1 
CHE: 









   (A.5) 
RBEmin = 1 
FRE: 
The FRE model is tissue dependent on αx, as seen in the equation below: 
RBEmax(LETd, αx) = 1 + 
0.008 Gy (keV μm)−3
αx
(LETd − 0.5 keV μm
−1),  (A.6) 
RBEmin = 1 
JON: 
The JON model is tissue dependent on αx and βx. The equations used is shown below: 
RBEmax(LETd, αx) = 1 + 






− 1)  (A.7) 
RBEmin(LETd, βx) = √1 + 






− 1),   (A.8) 
Where αu = 2.696 Gy
−1 x (1 − ex
−3.92Gy−1ax) and βu = 0.06 Gy
−2 x (1 − e−50Gy
−2βx) 
MAI: 
RBEmax(LETd, (α β)x⁄ ) = 1 + 
0.377 Gy
(α β)x⁄
LETd   (A.9) 
RBEmin = 1 
MCN: 
RBEmax(LETd, (α β)x⁄ ) = 0.99064 + 
0.35605 Gy (keV μm)−1
(α β)x⁄
LETd   (A.10) 
RBEmin(LETd, (α β)x⁄ ) = 1.1012 − 0.0038703 Gy
−
1
2(keV μm)−1√(α β)x⁄ LETd (A.11) 
PLR: 
RBEmax(LETd, (α β)x⁄ ) = 0.75 + 
0.00143 Gy (keV μm)−3
(α β)x⁄
LETd
3   (A.12) 
RBEmin(LETd, (α β)x⁄ ) = 1.24 +  0.00074 Gy
−1 (keV μm)−3 (α β)x⁄  LETd






Rørvik et al. developed two variable RBE models, using different statistical weighting for the 
two suggested models. The RORW model uses a quadratic weighted fit, whereas RORUW is 
based on a linear unweighted fit. 
Weighted: 
RBEmax(d(L), (α β)x⁄ ) = ∫ rmax(L, (α β)x⁄ ) d(L) dL
∞
0
   (A.14) 
Where  





 1 + 
Gy
(α β)x⁄






L3 − 9.92 x 10−5(keV μm)4L4) L < 37.0 keV μm −1
                                                                 1 +
10.5 Gy
(α β)x⁄
, L ≥ 37.0 keV m −1,
, (A.15) 
RBEmin = 1 
Unweighted:  
RBEmax(LETd, (α β)x⁄ ) = 1 + 
0.645 Gy (keV μm)−1
(α β)x⁄
LETd   (A.16) 
RBEmin = 1 
TIL: 
The Tilly model consists of two different fits that correspond to low and high (α/β)x. The 
equation used in this thesis is the fit to low (α/β)x, which is presented below; 
RBEmax(LETd) = 1 + 
0.309 Gy (keV μm)−1
(α β)x⁄
LETd   (A.17) 
RBEmin = 1 
UNK: 
The model by Unkelbach et al. is mainly a model for LET optimization, and is thereby not 
fitted to in vitro data. The equation for the UNK model is shown below: 
RBEmin = RBEmax = 1 + 0.04 (keV μm)
−1LETd   (A.18) 
WIL: 
As seen in the equation below, the WIL model is not tissue-dependent. We applied an (α⁄β)x of 
3.76 Gy.  
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RBEmax(LETd) = 0.892 + 0.179 (keV μm)
−1 LETd   (A.19) 
RBEmin = 1 
WED: 
RBEmax(LETd, (α β)x⁄ ) = 1 + 
0.434 Gy (keV μm)−1
(α β)x⁄
LETd   (A.20) 





Discrete RBEd values across all variable models for the different subgroups are presented in 
Table B.1 - B.3. Table B.4 shows the median value and corresponding range to each BSC 
across the selected set of models.  
Table B.1 Discrete RBEd values for the temporal lobe substructures across all variable RBE models. 
The models are shown in the column to the far left. The numbers following each model name indicate 
the input parameter of (α/β)x. Abbreviations: Amyg = Amygdala, Hippo = Hippocampus, L = left, R = 
right, Ent. Cor. = Entorhinal Cortex 
Model Structures 
 Amyg. L Amyg. R Ent. Cor. L Ent. Cor. R Hippo L Hippo R 
CAR 2 1.27 1.19 1.25 1.23 1.29 1.25 
CAR 3 1.21 1.13 1.18 1.17 1.21 1.17 
CHD 1.83 1.14 1.10 1.13 1.12 1.17 1.15 
CHD 8.73 1.21 1.14 1.19 1.17 1.21 1.18 
CHE 3.33 1.46 1.32 1.43 1.40 1.52 1.46 
FRE 2 1.09 1.06 1.08 1.08 1.10 1.09 
FRE 3 1.08 1.05 1.07 1.06 1.08 1.07 
JON 2 1.30 1.20 1.28 1.26 1.35 1.31 
JON 3 1.34 1.23 1.31 1.29 1.38 1.34 
MAI 2  1.25 1.18 1.24 1.22 1.30 1.27 
MAI 3 1.31 1.22 1.29 1.27 1.35 1.32 
MCN 2 1.27 1.20 1.25 1.24 1.30 1.27 
MCN 3 1.23 1.17 1.21 1.20 1.24 1.22 
PLR 2 1.08 1.07 1.06 1.06 1.03 1.01 
PLR 3 1.03 1.02 1.01 1.01 0.98 0.96 
RORW 2 1.23 1.17 1.22 1.21 1.27 1.25 
RORW 3 1.19 1.14 1.18 1.17 1.22 1.20 
RORUW 2 1.39 1.27 1.37 1.34 1.46 1.42 
RORUW 3 1.34 1.23 1.31 1.29 1.38 1.34 
TIL 2 1.25 1.15 1.23 1.21 1.28 1.23 
TIL 3 1.23 1.14 1.21 1.20 1.26 1.21 
UNK 1.14 1.09 1.12 1.11 1.13 1.11 
WED 2 1.27 1.19 1.25 1.24 1.32 1.29 
WED 3 1.23 1.16 1.21 1.20 1.26 1.23 
WIL 3.76 1.27 1.16 1.24 1.21 1.29 1.24 
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Table B.2 Discrete RBEd values for the ventricular substructures across all variable RBE models. The 
models are shown in the column to the far left. The numbers following each model name indicate the 
input parameter of (α/β)x. Abbreviations: Cing = Cingulum, Corp. = Corpus, L = left, R = right, SVZ = 
Subventricular zone 
Model RBEd 
 Cing. L Cing. R Corp. Col. Fornix SVZL SVZR 
CAR 2 1.15 1.15 1.14 1.22 1.15 1.15 
CAR 3 1.09 1.09 1.07 1.15 1.08 1.09 
CHD 1.83 1.10 1.10 1.10 1.13 1.10 1.10 
CHD 8.73 1.12 1.12 1.11 1.17 1.12 1.12 
CHE 3.33 1.31 1.31 1.30 1.40 1.31 1.31 
FRE 2 1.05 1.05 1.05 1.08 1.05 1.05 
FRE 3 1.04 1.04 1.04 1.06 1.04 1.04 
JON 2 1.20 1.20 1.19 1.26 1.20 1.20 
JON 3 1.21 1.21 1.20 1.29 1.21 1.21 
MAI 2  1.20 1.20 1.20 1.24 1.20 1.20 
MAI 3 1.22 1.22 1.22 1.28 1.22 1.22 
MCN 2 1.19 1.20 1.19 1.24 1.19 1.19 
MCN 3 1.15 1.15 1.15 1.20 1.15 1.15 
PLR 2 0.99 0.98 0.97 1.03 0.98 0.99 
PLR 3 0.94 0.94 0.92 0.98 0.93 0.94 
RORW 2 1.19 1.19 1.19 1.22 1.19 1.18 
RORW 3 1.15 1.15 1.15 1.18 1.15 1.15 
RORUW 2 1.28 1.29 1.28 1.35 1.28 1.28 
RORUW 3 1.23 1.23 1.22 1.29 1.22 1.22 
TIL 2 1.14 1.14 1.13 1.18 1.13 1.13 
TIL 3 1.12 1.12 1.12 1.7 1.11 1.12 
UNK 1.07 1.07 1.06 1.11 1.07 1.07 
WED 2 1.19 1.20 1.19 1.24 1.19 1.19 
WED 3 1.15 1.16 1.15 1.20 1.15 1.15 






Table B.3 Discrete RBEd values for the supratentorial substructures across all variable RBE models. 
The models are shown in the column to the far left. The numbers following each model name indicate 
the input parameter of (α/β)x. Abbreviations: Front. = Frontal, Par. = Parietal, Thal. = Thalamus, L = 
left, R = right 
Model RBEd 
 Front. L Front. R LFWM Par. L Par. R Thal. L Thal. R 
CAR 2 1.16 1.13 1.17 1.09 1.10 1.20 1.19 
CAR 3 1.09 1.06 1.08 1.01 1.02 1.13 1.12 
CHD 1.83 1.12 1.10 1.16 1.10 1.12 1.12 1.12 
CHD 8.73 1.13 1.11 1.13 1.09 1.09 1.15 1.15 
CHE 3.33 1.35 1.31 1.42 1.28 1.31 1.38 1.37 
FRE 2 1.06 1.05 1.08 1.04 1.05 1.07 1.07 
FRE 3 1.05 1.04 1.05 1.03 1.03 1.06 1.05 
JON 2 1.23 1.20 1.30 1.19 1.21 1.25 1.24 
JON 3 1.24 1.21 1.29 1.18 1.20 1.27 1.26 
MAI 2  1.24 1.21 1.31 1.22 1.24 1.23 1.22 
MAI 3 1.26 1.23 1.31 1.22 1.24 1.27 1.26 
MCN 2 1.21 1.19 1.25 1.17 1.19 1.23 1.22 
MCN 3 1.16 1.14 1.17 1.12 1.13 1.18 1.18 
PLR 2 0.94 0.93 0.85 0.86 0.84 1.00 1.01 
PLR 3 0.90 0.89 0.82 0.83 0.81 0.95 0.96 
RORW 2 1.22 1.19 1.28 1.20 1.22 1.22 1.21 
RORW 3 1.17 1.15 1.20 1.15 1.16 1.18 1.17 
RORUW 2 1.33 1.29 1.43 1.29 1.32 1.35 1.33 
RORUW 3 1.26 1.22 1.31 1.21 1.23 1.28 1.27 
TIL 2 1.17 1.11 1.20 1.12 1.12 1.21 1.18 
TIL 3 1.15 1.10 1.18 1.1 1.10 1.19 1.15 
UNK 1.08 1.06 1.07 1.05 1.05 1.09 1.09 
WED 2 1.23 1.20 1.29 1.20 1.22 1.24 1.23 
WED 3 1.18 1.15 1.21 1.14 1.15 1.19 1.18 
WIL 3.76 1.15 1.12 1.17 1.09 1.10 1.18 1.18 
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Table B.4 Median RBEd values (range in brackets) across the three selected variable RBE models (JON, 
MCN, RORW) for all analyzed BSCs. Both input parameters of (α/β)x  are included. Abbreviations: L = 
left, R = right, Ent. Cor. = Entorhinal Cortex, Hippo = Hippocampus, LFWM = Left frontal white matter, 




Median  [range] 
 JON MCN RORW 
Amygdala L 1.34 [1.27. 1.47] 1.26 [1.21. 1.35] 1.23 [1.18. 1.32] 
Amygdala R 1.33 [1.20. 1.44] 1.26 [1.17. 1.33] 1.22 [1.14. 1.29] 
Cerebellum 2.19 [1.73. 2.61] 1.71 [1.42. 2.17] 1.66 [1.39. 2.06] 
Cingulum L 1.24 [1.16. 1.44] 1.20 [1.13. 1.30] 1.19 [1.13. 1.30] 
Cingulum R 1.23 [1.16. 1.37] 1.19 [1.12. 1.28] 1.19 [1.13. 1.28] 
Circuit of Papez 1.32 [1.27. 1.41] 1.25 [1.20. 1.32] 1.22 [1.18. 1.28] 
Corpus Callosum 1.20 [1.15. 1.37] 1.17 [1.12. 1.23] 1.17 [1.12. 1.22] 
Ent. Cor. L 1.34 [1.28. 1.41] 1.25 [1.21. 1.34] 1.23 [1.18. 1.30] 
Ent. Cor. R 1.33 [1.24. 1.27] 1.24 [1.19. 1.339 1.21 [1.12. 1.29] 
Fornix 1.22 [1.17. 1.44] 1.19 [1.15. 1.24] 1.17 [1.13. 1.22] 
Frontal Lobe 1.21 [1.18. 1.44] 1.17 [1.13. 1.21] 1.17 [1.14. 1.22] 
Frontal Lobe  1.21 [1.18. 1.29] 1.17 [1.13. 1.22] 1.17 [1.14. 1.21] 
Hippo Head L 1.43 [1.32. 1.24] 1.30 [1.22. 1.45] 1.28 [1.21. 1.42] 
Hippo Head R 1.40 [1.27. 1.25] 1.27 [1.19. 1.43] 1.25 [1.18. 1.41] 
Hippo L 1.47 [1.31. 1.61] 1.31 [1.21. 1.51] 1.30 [1.20. 1.48] 
Hippo R 1.36 [1.28. 1.57] 1.28 [1.19. 1.43] 1.26 [1.19. 1.42] 
Hippo Tail L 1.53 [1.27. 2.17] 1.35 [1.17. 1.86] 1.34 [1.19. 1.80] 
Hippo Tail R 1.46 [1.23. 1.90] 1.30 [1.15. 1.67] 1.32 [1.17. 1.64] 
LFWM 1.37 [1.21. 2.33] 1.26 [1.14. 1.95] 1.30 [1.16. 1.90] 
Parietal Lobe L 1.20 [1.15. 1.27] 1.15 [1.11. 1.22] 1.18 [1.13. 1.26] 
Parietal Lobe R 1.19 [1.15. 1.49] 1.16 [1.11. 1.38] 1.18 [1.13. 1.40] 
SVZL 1.21 [1.15. 1.26] 1.17 [1.12. 1.23] 1.16 [1.13. 1.21] 
SVZR 1.21 [1.15. 1.27] 1.18 [1.12. 1.23] 1.17 [1.12. 1.21] 
Temporal Lobe L 1.33 [1.27. 1.45] 1.25 [1.19. 1.35] 1.24 [1.18. 1.33] 
Temporal Lobe R 1.32 [1.23. 1.41] 1.24 [1.17. 1.30] 1.23 [1.16. 1.29] 
Thalamus L 1.27 [1.21. 1.31] 1.21 [1.16. 1.25] 1.19 [1.15. 1.25] 





Median (range in brackets) across all patients of %V10Gy (Table C.1) and %V40Gy (Table 
C.2) for all BSCs for the selected set of models and RBE 1.1.  
Table C.1 Median (range in brackets) values for %V10Gy(RBE) for the three selected models and RBE 
1.1. Both input parameters of (α/β)x are included. Abbreviations: L = left, R = right, Ent. Cor. = 




%V10 Gy (RBE) 
Median  [range] [%] 
 RBE 1.1 JON MCN RORW 
Amygdala L 100 [100, 100] 100 [100, 100] 100 [100, 100] 100 [100, 100] 
Amygdala R 100 [100, 100] 100 [100, 100] 100 [100, 100] 100 [100, 100] 
Cerebellum 0 [0, 4] 1 [0, 6] 0 [0, 5] 0 [0, 5] 
Cingulum L 35 [13, 67] 38 [14, 67] 37 [13, 67] 37 [13, 67] 
Cingulum R 35 [14, 77] 38 [16, 77] 37 [15, 77] 37 [15, 77] 
Circuit of Papez 64 [58, 78] 66 [61, 80] 66 [60, 79] 65 [60, 79] 
Corpus Callosum 55 [36, 90] 58 [40, 90] 56 [38, 90] 57 [38, 91] 
Ent. Cor. L 100 [88, 100] 100 [92, 100] 100 [91, 100] 100 [91, 100] 
Ent. Cor. R 100 [97, 100] 100 [99, 100] 100 [98, 100] 100 [98, 100] 
Fornix 86 [51, 100] 87 [54, 100] 87 [52, 100] 87 [50, 100] 
Frontal Lobe 22 [17, 38] 24 [18, 40] 23 [18, 40] 24 [17, 41] 
Frontal Lobe  21 [16, 38] 22 [17, 41] 21 [16, 41] 22 [16, 41] 
Hippo Head L 82 [10, 100] 90 [19, 100] 88 [14, 100] 88 [14, 100] 
Hippo Head R 91 [58, 100] 100 [74, 100] 99 [67, 100] 99 [67, 100] 
Hippo L 42 [17, 61] 47 [24, 62] 46 [21, 62] 46 [21, 62] 
Hippo R 47 [18, 68] 55 [24, 76] 53 [21, 74] 53 [21, 74] 
Hippo Tail L 6 [0, 28] 10 [0, 37] 8 [0, 35] 8 [0, 35] 
Hippo Tail R 17 [0, 31] 26 [0, 50] 24 [0, 45] 24 [0, 44] 
LFWM 0 [0, 11] 0 [0, 13] 0 [0, 12] 0 [0, 13] 
Parietal Lobe L 3 [0, 13] 3 [0, 14] 3 [0, 14] 3 [0, 15] 
Parietal Lobe R 4 [0, 16] 4 [0, 17] 4 [0, 17] 4 [0, 17] 
SVZL 49 [42, 70] 51 [44, 75] 51 [43, 74] 51 [43, 75] 
SVZR 56 [31, 69] 57 [34, 71] 56 [32, 71] 57 [33, 71] 
Temporal Lobe L 26 [15, 47] 29 [18, 49] 28 [16, 49] 28 [16, 49] 
Temporal Lobe R 26 [23, 49] 30 [26, 51] 29 [24, 50] 29 [25, 51] 
Thalamus L 76 [37, 100] 79 [42, 100] 78 [39, 100] 78 [36, 100] 




Table C.2 Median (range in brackets) values for %V40Gy(RBE) for the three selected models and RBE 
1.1. Both input parameters of (α/β)x are included. Abbreviations: L = left, R = right, Ent. Cor. = 




%V40 Gy (RBE) 
Median  [range] [%] 
 RBE 1.1 JON MCN RORW 
Amygdala L 60 [22, 98] 88 [46, 100] 79 [37, 100] 76 [35, 100] 
Amygdala R 67 [32, 100] 90 [58, 100] 81 [48, 100] 78 [45, 100] 
Cerebellum 0 [0, 0] 0 [0, 1] 0 [0, 1] 0 [0, 1] 
Cingulum L 1 [0, 9] 3 [0, 10] 3 [0, 10] 3 [0, 10] 
Cingulum R 0 [0, 13] 0 [0, 15] 0 [0, 14] 0 [0, 14] 
Circuit of Papez 35 [17, 48] 41 [24, 54] 38 [21, 52]  38 [20, 52] 
Corpus Callosum 0 [0, 13] 2 [0, 18] 1 [0, 17] 1 [0, 16] 
Ent. Cor. L 75 [41, 97] 89 [57, 100] 84 [51, 100] 83 [49, 99] 
Ent. Cor. R 75 [51, 94] 86 [71, 98] 83 [63, 97] 82 [61, 97] 
Fornix 61 [27, 100] 61 [27, 100] 58 [26, 100] 55 [25, 99] 
Frontal Lobe 2 [1, 5] 2 [1, 6] 2 [1, 5] 2 [1, 5] 
Frontal Lobe  2 [1, 7] 3 [1, 9] 3 [1, 8] 3 [1, 8] 
Hippo Head L 11 [0, 52] 25 [0, 82] 18 [0, 74] 17 [0, 72] 
Hippo Head R 9 [0, 51] 23 [0, 69] 17 [0, 64] 16 [0, 62] 
Hippo L 3 [0, 20] 9 [0, 32] 7 [0, 29] 6 [0, 28] 
Hippo R 4 [0, 29] 9 [0, 39] 7 [0, 36] 7 [0, 35] 
Hippo Tail L 0 [0, 0] 0 [0, 4] 0 [0, 2] 0 [0, 2] 
Hippo Tail R 0 [0, 0] 0 [0, 2] 0 [0, 1] 0 [0, 1] 
LFWM 0 [0, 0] 0 [0, 0] 0 [0, 0] 0 [0, 0] 
Parietal Lobe L 0 [0, 0] 0 [0, 0] 0 [0, 0] 0 [0, 0] 
Parietal Lobe R 0 [0, 0] 0 [0, 0] 0 [0, 0] 0 [0, 0] 
SVZL 4 [0, 19] 7 [0, 25] 6 [0, 23] 6 [0, 22] 
SVZR 3 [0, 33] 5 [0, 38] 5 [0, 37] 4 [0, 37] 
Temporal Lobe L 4 [2, 9] 6 [4, 12] 5 [3, 11] 5 [3, 11] 
Temporal Lobe R 5 [3, 9] 7 [4, 12] 6 [4, 12] 6 [4, 11] 
Thalamus L 34 [0, 81] 41 [2, 92] 39 [1, 90] 38 [1, 89] 




Discrete IQ change scores obtained by Equation (6.2 – 6.10) are shown in Table D.1 – D.9. The 
calculated p-value (RBE 1.1 compared with each variable RBE model) is shown in the lowest 
row.  If the variable RBE model systematically resulted in higher or lower values across all 
patients, the calculated p-value was 0.005. For all tables in Appendix D, the patient number is 
shown in the column to the far left.  
Table D.10 presents discrete values of the change in delayed verbal memory score (Eq. 6.13), 
whereas table D.11 presents discrete values for the risk of memory impairment obtained by Eq. 
6.14. 
Table D.1 This table presents the IQ score change values obtained from Eq. (6.2). The equation 
estimates the change in IQ score based on the dose/volume intervals for the brain. The patient number 
is shown in the column to the far left. The p-values are shown in the row at the bottom.  
# IQ score change 
Brain 
 RBE 1.1 JON MCN RORW 
Input parameter of (α/β)x 
2 3 2 3 2 3 
1 -8.9 -8.5 -7.8 -8.5 -9.3 -8.9 -9.2 
2 -9.5 -8.8 -8.2 -9.1 -9.7 -9.6 -9.7 
3 -8.1 -7.0 -7.2 -7.2 -7.9 -7.6 -8.2 
4 -9.5 -8.6 -8.3 -8.9 -9.5 -9.4 -9.6 
5 -8.8 -8.2 -7.7 -8.4 -9.1 -8.9 -9.0 
6 -9.5 -9.3 -8.7 -9.4 -9.8 -9.7 -9.7 
7 -9.1 -8.5 -8.1 -8.6 -9.3 -9.1 -9.3 
8 -9.5 -9.1 -8.7 -9.3 -9.7 -9.7 -9.7 
9 -9.4 -9.1 -8.9 -9.2 -9.5 -9.5 -9.5 
10 -9.5 -9.2 -8.3 -9.5 -10.0 -9.9 -9.9 








Table D.2 This table presents the IQ score change values obtained from Eq. (6.3). The equation 
estimates the change in IQ score based on the dose/volume intervals for the supratentorial brain. The 
patient number is shown in the column to the far left. The p-values are shown in the row at the bottom.  
# IQ score change 
Supratentorial brain  
 RBE 1.1 JON MCN RORW 
Input parameter of (α/β)x 
2 3 2 3 2 3 
1 -9.0 -8.6 -7.9 -8.8 -9.4 -9.3 -9.3 
2 -8.8 -8.1 -7.5 -8.4 -9.0 -8.9 -9.0 
3 -8.5 -7.5 -7.7 -7.7 -8.3 -8.1 -8.6 
4 -8.9 -7.9 -7.7 -8.2 -8.9 -8.9 -9.1 
5 -8.2 -7.8 -7.3 -8.0 -8.5 -8.4 -8.5 
6 -8.9 -8.7 -8.0 -8.9 -9.3 -9.2 -9.1 
7 -8.7 -7.9 -7.6 -8.1 -8.8 -8.7 -8.9 
8 -8.5 -8.4 -8.0 -8.5 -8.8 -8.7 -8.7 
9 -8.9 -8.5 -8.2 -8.6 -9.1 -9.0 -9.0 
10 -9.2 -8.9 -7.7 -9.1 -9.8 -9.7 -9.7 
p-value 0.005 0.005 0.005 0.005 0.09 0.005 
 
Table D.3 This table presents the IQ score change values obtained from Eq. (6.4). The equation 
estimates the change in IQ score based on the dose/volume intervals for the left temporal lobe. The 
patient number is shown in the column to the far left. The p-values are shown in the row at the bottom.  
# IQ score change 
Left temporal lobe 
 RBE 1.1 JON MCN RORW 
Input parameter of (α/β)x 
2 3 2 3 2 3 
1 -9.3 -9.1 -9.0 -9.2 -9.4 -9.4 -9.4 
2 -9.3 -9.0 -8.9 -9.1 -9.2 -9.2 -9.3 
3 -9.5 -8.8 -8.8 -8.9 -9.3 -9.2 -9.6 
4 -9.0 -8.7 -8.6 -8.9 -9.1 -9.1 -9.2 
5 -9.0 -8.3 -8.1 -8.6 -9.4 -9.3 -9.3 
6 -9.1 -8.6 -8.5 -8.8 -9.3 -9.2 -9.2 
7 -8.9 -8.7 -8.7 -8.8 -9.0 -9.0 -9.0 
8 -9.2 -8.9 -8.7 -9.0 -9.3 -9.2 -9.2 
9 -8.9 -8.7 -8.6 -8.8 -9.0 -8.9 -9.0 
10 -8.8 -8.6 -8.3 -8.9 -9.2 -9.1 -9.1 
p-value 0.005 0.005 0.005 0.005 0.31 0.005 
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Table D.4 This table presents the IQ score change values obtained from Eq. (6.5). The equation 
estimates the change in IQ score based on the dose/volume intervals for the brain. The patient number 
is shown in the column to the far left. The p-values are shown in the row at the bottom.  
# IQ score change 
Brain 
 RBE 1.1 JON MCN RORW 
Input parameter of (α/β)x 
2 3 2 3 2 3 
1 -1.9 -2.0 -2.0 -2.0 -1.9 -2.0 -2.0 
2 -1.0 -1.2 -1.2 -1.2 -1.1 -1.2 -1.1 
3 -1.1 -1.1 -1.2 -1.2 -1.1 -1.2 -1.1 
4 -0.9 -1.1 -1.0 -1.0 -1.0 -1.1 -1.0 
5 -1.4 -1.5 -1.5 -1.5 -1.4 -1.5 -1.4 
6 -0.9 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 
7 -1.2 -1.3 -1.3 -1.3 -1.2 -1.3 -1.2 
8 -0.8 -0.9 -0.9 -0.9 -0.9 -0.9 -0.9 
9 -0.7 -0.8 -0.8 -0.8 -0.7 -0.8 -0.7 
10 -1.5 -1.6 -1.6 -1.6 -1.5 -1.6 -1.6 
p-value 0.005 0.005 0.005 0.005 0.005 0.005 
 
Table D.5 This table presents the IQ score change values obtained from Eq. (6.6). The equation 
estimates the change in IQ score based on the dose/volume intervals for the supratentorial brain. The 
patient number is shown in the column to the far left. The p-values are shown in the row at the bottom.  
# IQ score change 
Supratentorial brain 
 RBE 1.1 JON MCN RORW 
Input parameter of (α/β)x 
2 3 2 3 2 3 
1 -1.8 -3.3 -3.4 -3.3 -3.1 -3.2 -2.9 
2 -0.9 -1.9 -1.9 -1.8 -1.7 -1.8 -1.6 
3 -0.9 -1.4 -1.5 -1.6 -1.5 -1.5 -1.4 
4 -0.9 -1.6 -1.6 -1.6 -1.5 -1.6 -1.4 
5 -1.1 -2.2 -2.2 -2.1 -2.0 -2.0 -1.8 
6 -0.8 -1.7 -1.8 -1.7 -1.6 -1.6 -1.5 
7 -1.0 -2.0 -2.0 -2.0 -1.8 -1.9 -1.7 
8 -0.6 -1.2 -1.2 -1.1 -1.0 -1.1 -1.0 
9 -0.6 -1.2 -1.2 -1.2 -1.1 -1.1 -1.0 
10 -1.3 -3.0 -3.1 -2.9 -2.7 -2.8 -2.5 




Table D.6 This table presents the IQ score change values obtained from Eq. (6.7). The equation 
estimates the change in IQ score based on the dose/volume intervals for the left temporal lobe. The 
patient number is shown in the column to the far left. The p-values are shown in the row at the bottom.  
# IQ score change 
Left temporal lobe 
 RBE 1.1 JON MCN RORW 
Input parameter of (α/β)x 
2 3 2 3 2 3 
1 -0.9 -1.1 -1.1 -1.1 -1.0 -1.1 -1.0 
2 -0.9 -1.1 -1.1 -1.1 -1.0 -1.1 -1.0 
3 -1.5 -1.7 -1.8 -1.8 -1.7 -1.9 -1.7 
4 -1.3 -1.6 -1.5 -1.5 -1.4 -1.5 -1.4 
5 -2.6 -3.0 -3.0 -3.0 -2.8 -3.1 -2.9 
6 -1.6 -1.9 -1.9 -1.9 -1.7 -2.0 -1.7 
7 -1.6 -1.9 -1.9 -1.9 -1.8 -1.9 -1.8 
8 -1.4 -1.7 -1.7 -1.6 -1.5 -1.7 -1.5 
9 -1.1 -1.4 -1.4 -1.4 -1.3 -1.4 -1.3 
10 -1.9 -2.2 -2.2 -2.2 -2.1 -2.2 -2.1 
p-value 0.005 0.005 0.005 0.005 0.005 0.005 
 
Table D.7 This table presents the IQ score change values obtained from Eq. (6.8). The equation 
estimates the change in IQ score based on the mean dose to the brain. The patient number is shown in 
the column to the far left. The p-values are shown in the row at the bottom.  
# IQ score change 
Brain 
 RBE 1.1 JON MCN RORW 
Input parameter of (α/β)x 
2 3 2 3 2 3 
1 -2.3 -2.6 -2.6 -2.5 -2.4 -2.5 -2.4 
2 -1.5 -1.7 -1.8 -1.7 -1.6 -1.7 -1.6 
3 -1.3 -1.5 -1.5 -1.5 -1.4 -1.5 -1.4 
4 -1.4 -1.6 -1.6 -1.6 -1.5 -1.6 -1.5 
5 -1.8 -2.1 -2.1 -2.0 -2.0 -2.0 -1.9 
6 -1.5 -1.7 -1.7 -1.6 -1.6 -1.6 -1.6 
7 -1.6 -1.8 -1.8 -1.8 -1.7 -1.8 -1.7 
8 -1.2 -1.4 -1.5 -1.4 -1.3 -1.4 -1.3 
9 -1.1 -1.3 -1.3 -1.2 -1.2 -1.2 -1.2 
10 -2.1 -2.3 -2.4 -2.3 -2.2 -2.3 -2.2 




Table D.8 This table presents the IQ score change values obtained from Eq. (6.9). The equation 
estimates the change in IQ score based on the mean dose to the supratentorial brain. The patient number 
is shown in the column to the far left. The p-values are shown in the row at the bottom.  
# IQ score change 
Supratentorial brain  
 RBE 1.1 JON MCN RORW 
Input parameter of (α/β)x 
2 3 2 3 2 3 
1 -2.3 -2.6 -2.6 -2.5 -2.4 -2.5 -2.4 
2 -1.5 -1.7 -1.7 -1.7 -1.6 -1.7 -1.6 
3 -1.3 -1.5 -1.4 -1.4 -1.4 -1.4 -1.4 
4 -1.4 -1.6 -1.6 -1.6 -1.5 -1.6 -1.5 
5 -1.8 -2.0 -2.0 -2.0 -1.9 -2.0 -1.9 
6 -1.6 -1.8 -1.8 -1.7 -1.7 -1.7 -1.7 
7 -1.6 -1.8 -1.8 -1.8 -1.7 -1.8 -1.7 
8 -1.2 -1.3 -1.3 -1.3 -1.2 -1.3 -1.2 
9 -1.2 -1.3 -1.3 -1.3 -1.2 -1.3 -1.2 
10 -2.1 -2.4 -2.4 -2.4 -2.3 -2.3 -2.3 
p-value 0.005 0.005 0.005 0.005 0.005 0.005 
 
Table D.9 This table presents the IQ score change values obtained from Eq. (6.10). The equation 
estimates the change in IQ score based on the mean dose to the left temporal lobe. The patient number 
is shown in the column to the far left. The p-values are shown in the row at the bottom.  
# IQ score change 
Left temporal lobe 
 RBE 1.1 JON MCN RORW 
Input parameter of (α/β)x 
2 3 2 3 2 3 
1 -0.9 -1.1 -1.1 -1.1 -1.0 -1.1 -1.0 
2 -0.9 -1.1 -1.1 -1.1 -1.0 -1.1 -1.0 
3 -1.5 -1.7 -1.8 -1.8 -1.7 -1.9 -1.7 
4 -1.3 -1.6 -1.5 -1.5 -1.4 -1.5 -1.4 
5 -2.6 -3.0 -3.0 -3.0 -2.8 -3.1 -2.9 
6 -1.6 -1.9 -1.9 -1.9 -1.7 -2.0 -1.7 
7 -1.6 -1.9 -1.9 -1.9 -1.8 -1.9 -1.8 
8 -1.4 -1.7 -1.7 -1.6 -1.5 -1.7 -1.5 
9 -1.1 -1.4 -1.4 -1.4 -1.3 -1.4 -1.3 
10 -1.9 -2.2 -2.2 -2.2 -2.1 -2.2 -2.1 




Table D.10 This table presents the estimated risk of memory impairment from Eq. (6.13). The patient 
number is shown in the column to the far left.  
# Risk of memory impairment 
 RBE 1.1 JON MCN RORW 
Input parameter of (α/β)x 
2 3 2 3 2 3 
1 34 % 36 % 36 % 36 % 35 % 36 % 35 % 
2 33 % 35 % 35 % 34 % 34 % 34 % 34 % 
3 39 % 42 % 42 % 41 % 40 % 41 % 40 % 
4 36 % 39 % 40 % 39 % 38 % 38 % 38 % 
5 45 % 49 % 49 % 48 % 47 % 48 % 47 % 
6 43 % 46 % 46 % 45 % 44 % 45 % 44 % 
7 37 % 40 % 40 % 39 % 39 % 39 % 39 % 
8 36 % 38 % 38 % 37 % 37 % 37 % 37 % 
9 38 % 40 % 41 % 40 % 39 % 40 % 39 % 
10 40 % 44 % 45 % 43 % 42 % 43 % 42 % 
 
Table D.11 This table presents the estimated delayed verbal memory score from Eq. (6.14). The patient 
number is shown in the column to the far left.  
# Delayed verbal memory score 
 RBE 1.1 JON MCN RORW 
Input parameter of (α/β)x 
2 3 2 3 2 3 
1 -0.62 -0.68 -0.68 -0.67 -0.66 -0.66 -0.65 
2 -0.68 -0.76 -0.76 -0.74 -0.73 -0.74 -0.73 
3 -0.86 -0.91 -0.91 -0.9 -0.88 -0.9 -0.89 
4 -0.64 -0.7 -0.7 -0.68 -0.67 -0.68 -0.67 
5 -0.97 -0.99 -0.99 -0.99 -0.98 -0.99 -0.98 
6 -0.96 -1.02 -1.02 -1.01 -0.99 -1.01 -0.99 
7 -0.58 -0.63 -0.63 -0.62 -0.6 -0.61 -0.6 
8 -0.89 -0.97 -0.97 -0.95 -0.93 -0.95 -0.93 
9 -0.71 -0.79 -0.79 -0.77 -0.76 -0.77 -0.75 
10 -0.83 -0.93 -0.93 -0.91 -0.89 -0.9 -0.88 
 
